Document:

Exhibit
10.32

 

Execution
Copy

 

***TEXT
OMITTED AND SUBMITTED SEPARATELY

PURSUANT
TO CONFIDENTIAL TREATMENT REQUEST

UNDER
17 C.F.R. SECTIONS 200.80(b)(4) AND 230.406

 

 

 

 

MANUFACTURING
AGREEMENT

 

BY
AND BETWEEN

 

BAYER
HEALTHCARE LLC

 

BIOLOGICAL
PRODUCTS DIVISION

 

BERKELEY,
CALIFORNIA

 

AND

 

TALECRIS
BIOTHERAPEUTICS, INC.

 

RALEIGH,
NORTH CAROLINA

 

 

TABLE OF CONTENTS

 

	
   

  	
   

  	
   

  	
  Page

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE 1

  	
  TERM

  	
   

  	
  1

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE 2

  	
  CUSTOM
  MANUFACTURING SERVICES

  	
   

  	
  2

  
	
   

  	
   

  	
   

  	
   

  
	
  2.1

  	
  Volume Requirements

  	
   

  	
  2

  
	
   

  	
   

  	
   

  	
   

  
	
  2.2

  	
  Manufacturing Services

  	
   

  	
  2

  
	
   

  	
   

  	
   

  	
   

  
	
  2.3

  	
  Supply of Inputs

  	
   

  	
  2

  
	
   

  	
   

  	
   

  	
   

  
	
  2.4

  	
  Product Supply Forecasts

  	
   

  	
  3

  
	
   

  	
   

  	
   

  	
   

  
	
  2.5

  	
  Manufacturing of the Products

  	
   

  	
  3

  
	
   

  	
   

  	
   

  	
   

  
	
  2.6

  	
  Yield

  	
   

  	
  4

  
	
   

  	
   

  	
   

  	
   

  
	
  2.7

  	
  Samples

  	
   

  	
  5

  
	
   

  	
   

  	
   

  	
   

  
	
  2.8

  	
  Testing

  	
   

  	
  5

  
	
   

  	
   

  	
   

  	
   

  
	
  2.9

  	
  Order and Availability

  	
   

  	
  5

  
	
   

  	
   

  	
   

  	
   

  
	
  2.10

  	
  Shipments

  	
   

  	
  6

  
	
   

  	
   

  	
   

  	
   

  
	
  2.11

  	
  Contract Review and Onsite Personnel

  	
   

  	
  6

  
	
   

  	
   

  	
   

  	
   

  
	
  2.12

  	
  Bayer Processing

  	
   

  	
  6

  
	
   

  	
   

  	
   

  	
   

  
	
  2.13

  	
  Risk of Loss

  	
   

  	
  6

  
	
   

  	
   

  	
   

  	
   

  
	
  2.14

  	
  Debarment

  	
   

  	
  7

  
	
   

  	
   

  	
   

  	
   

  
	
  2.15

  	
  Cooperation of the Parties

  	
   

  	
  7

  
	
   

  	
   

  	
   

  	
   

  
	
  2.16

  	
  Records

  	
   

  	
  7

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  3

  	
  PRICE AND
  PAYMENT

  	
   

  	
  7

  
	
   

  	
   

  	
   

  	
   

  
	
  3.1

  	
  Charge for Manufacturing Services

  	
   

  	
  7

  
	
   

  	
   

  	
   

  	
   

  
	
  3.2

  	
  Adjustment to Prices

  	
   

  	
  8

  
	
   

  	
   

  	
   

  	
   

  
	
  3.3

  	
  Price Adjustment Calculation

  	
   

  	
  8

  
	
   

  	
   

  	
   

  	
   

  
	
  3.4

  	
  Payments

  	
   

  	
  8

  
	
   

  	
   

  	
   

  	
   

  
	
  3.5

  	
  Payment Disputes

  	
   

  	
  8

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  4

  	
  EARLY
  TERMINATION

  	
   

  	
  8

  
	
   

  	
   

  	
   

  	
   

  
	
  4.1

  	
  Termination for Cause

  	
   

  	
  8

  
	
   

  	
   

  	
   

  	
   

  
	
  4.2

  	
  Effect of Termination

  	
   

  	
  9

  
	
   

  	
   

  	
   

  	
   

  
	
  4.3

  	
  Remedies

  	
   

  	
  10

  
	
   

  	
   

  	
   

  	
   

  
	
  4.4

  	
  Survival

  	
   

  	
  10

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  5

  	
  COMPLIANCE

  	
   

  	
  10

  

 

 

 

	
   

  	
   

  	
   

  	
   

  
	
  5.1

  	
  Compliance with Regulations

  	
   

  	
  10

  
	
   

  	
   

  	
   

  	
   

  
	
  5.2

  	
  Audit

  	
   

  	
  11

  
	
   

  	
   

  	
   

  	
   

  
	
  5.3

  	
  Regulatory Filings

  	
   

  	
  11

  
	
   

  	
   

  	
   

  	
   

  
	
  5.4

  	
  Regulatory Approvals

  	
   

  	
  11

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  6

  	
  NONCONFORMING
  PRODUCT AND RECALLS

  	
   

  	
  12

  
	
   

  	
   

  	
   

  	
   

  
	
  6.1

  	
  Nonconforming Product

  	
   

  	
  12

  
	
   

  	
   

  	
   

  	
   

  
	
  6.2

  	
  General Requirements

  	
   

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
  6.3

  	
  Distribution and Use Records

  	
   

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
  6.4

  	
  Adverse Events

  	
   

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
  6.5

  	
  Customer Notification of Adverse Reactions

  	
   

  	
  13

  
	
   

  	
   

  	
   

  	
   

  
	
  6.6

  	
  Withdrawals and Recalls

  	
   

  	
  14

  
	
   

  	
   

  	
   

  	
   

  
	
  6.7

  	
  Customer Complaints

  	
   

  	
  14

  
	
   

  	
   

  	
   

  	
   

  
	
  6.8

  	
  Responsibility

  	
   

  	
  14

  
	
   

  	
   

  	
   

  	
   

  
	
  6.9

  	
  Deviation Report

  	
   

  	
  14

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  7

  	
  CONFIDENTIALITY

  	
   

  	
  15

  
	
   

  	
   

  	
   

  	
   

  
	
  7.1

  	
  Confidentiality Obligations

  	
   

  	
  15

  
	
   

  	
   

  	
   

  	
   

  
	
  7.2

  	
  Exceptions

  	
   

  	
  15

  
	
   

  	
   

  	
   

  	
   

  
	
  7.3

  	
  Term of Obligations

  	
   

  	
  15

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  8

  	
  WARRANTIES
  AND COVENANTS

  	
   

  	
  15

  
	
   

  	
   

  	
   

  	
   

  
	
  8.1

  	
  General

  	
   

  	
  15

  
	
   

  	
   

  	
   

  	
   

  
	
  8.2

  	
  Intellectual Property

  	
   

  	
  16

  
	
   

  	
   

  	
   

  	
   

  
	
  8.3

  	
  Representations and Warranties

  	
   

  	
  17

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  9

  	
  INDEMNITIES
  AND DAMAGES

  	
   

  	
  19

  
	
   

  	
   

  	
   

  	
   

  
	
  9.1

  	
  Indemnifications

  	
   

  	
  19

  
	
   

  	
   

  	
   

  	
   

  
	
  9.2

  	
  Indemnification Process

  	
   

  	
  19

  
	
   

  	
   

  	
   

  	
   

  
	
  9.3

  	
  Insurance

  	
   

  	
  20

  
	
   

  	
   

  	
   

  	
   

  
	
  9.4

  	
  Liquidated Damages For Failure To Deliver
  Products

  	
   

  	
  20

  
	
   

  	
   

  	
   

  	
   

  
	
  9.5

  	
  Insurance Recoveries

  	
   

  	
  23

  
	
   

  	
   

  	
   

  	
   

  
	
  9.6

  	
  Aggregate Caps

  	
   

  	
  23

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  10

  	
  DISCLAIMER

  	
   

  	
  23

  
					

 

ii

 

	
  ARTICLE
  11

  	
  FORCE
  MAJEURE

  	
   

  	
  23

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE
  12

  	
  MISCELLANEOUS

  	
   

  	
  24

  
	
   

  	
   

  	
   

  	
   

  
	
  12.1

  	
  Consent to Assignment

  	
   

  	
  24

  
	
   

  	
   

  	
   

  	
   

  
	
  12.2

  	
  Entire Agreement and Amendments

  	
   

  	
  24

  
	
   

  	
   

  	
   

  	
   

  
	
  12.3

  	
  Notices

  	
   

  	
  25

  
	
   

  	
   

  	
   

  	
   

  
	
  12.4

  	
  Independent Contractor

  	
   

  	
  26

  
	
   

  	
   

  	
   

  	
   

  
	
  12.5

  	
  Non-Waiver

  	
   

  	
  26

  
	
   

  	
   

  	
   

  	
   

  
	
  12.6

  	
  Choice of Law

  	
   

  	
  26

  
	
   

  	
   

  	
   

  	
   

  
	
  12.7

  	
  Captions

  	
   

  	
  26

  
	
   

  	
   

  	
   

  	
   

  
	
  12.8

  	
  Severability

  	
   

  	
  26

  
	
   

  	
   

  	
   

  	
   

  
	
  12.9

  	
  Dispute Resolution

  	
   

  	
  26

  
	
   

  	
   

  	
   

  	
   

  
	
  12.10

  	
  Defined Terms

  	
   

  	
  28

  
	
   

  	
   

  	
   

  	
   

  
	
  12.11

  	
  Set-Off

  	
   

  	
  28

  

 

iii

 

MANUFACTURING AGREEMENT

 

This MANUFACTURING AGREEMENT (this “Agreement”) is entered into as of March
31, 2005 (the “Effective
Date”) by and between Talecris
Biotherapeutics, Inc. (f/k/a NPS BioTherapeutics, Inc.) (“Purchaser”) and Bayer
HealthCare LLC, Biological Products Division (“Bayer,” along with Purchaser, the “Parties”).

 

WHEREAS, Bayer, Talecris Holdings, LLC (f/k/a NPS Bio Holdings, LLC),
Talecris Biotherapeutics Holdings Corp. and Purchaser have entered into that
certain Amended and Restated Joint Contribution Agreement, dated as of March
30, 2005 (the “Contribution
Agreement”);

 

WHEREAS, Purchaser desires to engage Bayer as a custom manufacturer of
Column Eluate and ATM (the “Products”) at its facility located at Berkeley,
California (“Bayer
Facility”) processing Fraction IV-I and PEG Paste (the “Inputs”) supplied by
Purchaser;

 

WHEREAS, Purchaser will, upon receipt of Column Eluate from Bayer,
further process and purify the Column Eluate into an injectable therapeutic
product (“Prolastin”);

 

WHEREAS, Purchaser will engage in the marketing, sale, storage, and
distribution of ATIII and Prolastin; and

 

WHEREAS, Purchaser and Bayer wish to set forth their mutual agreements
and understandings regarding the manufacture of the Products by Bayer on behalf
of Purchaser. -

 

NOW, THEREFORE; for and in consideration of the premises and the mutual
covenants contained herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties hereto do
hereby agree as follows:

 

ARTICLE 1 TERM

This Agreement shall have an initial term commencing on the Effective
Date and terminating on December 31, 2006 (“Initial Term”) unless earlier terminated
as provided in Article 4 below. The Initial Term may be renewed for two one (1)
year periods at the option of Purchaser (each, an “Extended Term”), and
thereafter for one additional one (1) year period upon the terms and conditions
set forth below (“Final
Term”). Purchaser shall give Bayer at least nine (9) months’
written notice prior to the end of the then expiring term as to each of the
Extended Terms, and shall give Bayer at least twelve (12) months’ written
notice prior to the end of the second Extended Term as to a proposed Final
Term. The Initial Term, each Extended Term and the Final Term shall
collectively constitute the “Term”. As promptly as practicable after Purchaser gives
notice of the Final Term, Bayer shall within ninety (90) days of such notice
advise Purchaser of the price calculation, subject to adjustment under Article
3 and subject to reflecting the full costs of operating the facility solely for
the purpose of manufacturing the Products. The Parties shall then engage in
good faith negotiations for a period of three (3) months. If the Parties cannot
reach an agreement to adjust the Price within such three (3) month period, then
Purchaser shall not have the option to extend for such Final Term.

 

 

ARTICLE 2 CUSTOM
MANUFACTURING SERVICES

2.1           Volume
Requirements. With respect to each calendar year during the Initial Term,
Bayer shall make available to Purchaser, and Purchaser may purchase from Bayer,
Column Eluate and ATIII in the quantities set forth in Exhibit A, attached hereto and
incorporated herein by reference (which conform to the Product Specifications
(as defined in Section 2.2 below)) (as adjusted herein, the “Column Eluate Required Quantity”
and the “ATIII Required
Quantity”, respectively, and collectively, the “Required Quantity”).
Upon providing a notice of renewal for the Extended Term in accordance with
Article 1, Purchaser shall amend Exhibit A
to set forth the amount of Products that Bayer shall make available to
Purchaser and that Purchaser may purchase from Bayer during the Extended Term;
provided that, the Column Eluate Required Quantity cannot exceed one hundred
twenty percent (120%) of that amount shown on Exhibit A then in effect on the date the notice of renewal
is provided and the ATIII Required Quantity cannot exceed that amount set forth
on Exhibit A in effect as
of the Effective Date. Subject to the other provisions contained herein,
including without limitation, Section 2.4 below, in each. calendar year during
the Term of this Agreement, Purchaser may request in its sole discretion, and
Bayer shall supply, (a) a minimum of seventy-five percent (75%) of the Column
Eluate Required Quantity and a maximum of one hundred fifteen percent (115%) of
the Column Eluate Required Quantity; and (b) a maximum of [***] vials of ATIII (each as determined
after deducting quantities representing Nonconforming Product (as defined in
Section 6.1 below)). Subject to the foregoing, on or prior to October 1 of each
calendar year, the Required Quantity applicable for the immediately following
calendar year shall be reviewed and may be revised by mutual agreement of the
Parties. For each calendar year during the Term, Purchaser shall make available
to Bayer that quantity of Inputs meeting the Input Specifications (each as
defined in Section 2.3 below) necessary for Bayer-to manufacture each Binding
Production Forecast as set forth .in Section 2.4 (“Required Inputs”). In
the event that Purchaser provides less than one hundred percent (100%) of the
Required Inputs, then the Binding Production Forecast shall be adjusted to
reflect the supply of Inputs provided by Purchaser to Bayer. Notwithstanding
the foregoing, in no event shall Purchaser provide in each calendar year of the
Term (other than the Final Term) (a) less than seventy-five percent (75%) of
the Required Inputs and (b) less than [***]
kilograms of Fraction IV-I Paste manufactured by Purchaser at the Purchaser’s
Facility (the “Minimum
Bayer IV-I Paste Requirement”) (each as determined after
deducting quantities representing Nonconforming Inputs (as defined in Section
6.1 below)).

 

2.2           Manufacturing
Services. During the Term of this Agreement, Bayer shall process the Inputs
provided by Purchaser into the Products (the “Manufacturing Services”). The Column
Eluate supplied by Bayer shall meet the specifications set forth in Exhibit B and the ATIII supplied by
Bayer shall meet the specifications set forth in Exhibit C,
each such exhibit as attached hereto and incorporated herein by reference, and
each of which may be amended from time-to-time by mutual written agreement of
the Parties (the “Product
Specifications”). The Product Specifications in effect as of the
date hereof are those that were in effect as of the date of execution of the
Contribution Agreement.

 

2.3           Supply
of Inputs. Subject to the terms and conditions of this Agreement, during
the Term, Purchaser shall supply to Bayer Fraction IV-I Paste meeting the
specifications set forth in Exhibit D
and PEG Paste meeting the specifications set forth in Exhibit E each such exhibit as attached
hereto and incorporated herein by reference, and each of which may be amended
from 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

2

 

time-to-time by mutual written agreement of the Parties, and such other
specifications and requirements as set forth in the Manufacturing Agreements
attached hereto as Exhibits F and G, as applicable (collectively, the “Input Specifications”),
at such times and in such amounts, as is required for Bayer to process and
supply the Products in accordance with the Binding Production Forecasts (as
defined in Section 2.4 below). In providing that volume of Required Inputs
meeting those requirements set forth in Section 2.1 above, unless otherwise
agreed in writing by the Parties, Purchaser shall during each calendar. year of
the Term of this Agreement supply Bayer with Inputs (including the Minimum
Bayer IV-I Paste Requirement) in such amounts as is necessary for Bayer to process
amounts of ATIII and Column Eluate reflected in the Binding Production
Forecasts, Purchaser shall maintain at the Bayer Facility an inventory of
Fraction IV-I Paste manufactured by Purchaser at Purchaser’s Facility, and
meeting the Input Specifications, equal to [***]
kilograms, to be used by Bayer in the production of the Products. The Inputs
supplied by Purchaser shall be deemed at all times to be the property of
Purchaser. Bayer shall be responsible for all Inputs while such Inputs are in
Bayer’s possession at the Bayer Facility. Purchaser shall be responsible for
arranging the shipment of the Inputs from the facility located in Clayton,
North Carolina (“Purchaser’s
Facility”).

 

2.4           Product
Supply Forecasts. Upon the Effective Date, Purchaser shall provide Bayer
with a twelve (12) month rolling forecast of Purchaser’s estimated production
and supply needs for each of the Products by calendar month (the “Production Forecast”).
Such Production Forecast of Purchaser’s future requirements, as may be revised
from time to time, shall be attached hereto as Exhibit A, and incorporated herein by reference. Purchaser
shall provide an updated twelve (12) month rolling Production Forecast on or
about the commencement of each calendar month. The first six (6) months of each
rolling twelve (12) month forecast for Column Eluate shall be binding (the “Column Eluate Binding Production
Forecast”), and the last six (6) months of the Column Eluate
rolling, forecast shall be good faith estimates and shall not be binding on the
Parties. The first six (6) months of each rolling twelve (12) month forecast
for ATIII shall be binding (the “ATIII Binding Production Forecast” and
together with the Column Eluate Binding Production Forecast, the “Binding Production Forecast”),
and the last six (6) months of ATIII rolling forecast shall be good faith
estimates and shall not be binding on the Parties. In each calendar year, the
aggregate Binding Production Forecasts for such period shall equal at least
seventy-five percent (75%) of the Column Eluate Required Quantity and at least
one hundred percent (100%) of the ATIII Required Quantity. In the event that
the actual Products requested by Purchaser (as determined based on Orders (as
defined in Section 2.9 below) placed by Purchaser for Products meeting the
Product Specifications in accordance with Section 2.9 below) are less than
those set forth in a Binding Production Forecast, the Parties agree and
acknowledge that Purchaser nonetheless shall be obligated to pay for the
Products set forth in such Binding Production Forecast at the prices set forth
in Section 3.1, as may be revised from time to time.

 

2.5           Manufacturing
of the Products. Bayer shall manufacture, process, store, distribute, test,
transport, dispose, deliver and otherwise handle the Products and the Inputs at
all times in full compliance with, as applicable, cGMPs (as defined in Section
5.1), other Regulations (as defined in Section 5.1), the Product
Specifications, the Manufacturing Agreement (for manufacturing Fraction IV-I/PEG
Paste into the Column Eluate), attached hereto as Exhibit F and incorporated herein by reference, the
Manufacturing Agreement (for manufacturing Fraction IV-I Paste into ATIII),
attached hereto as Exhibit G
and incorporated herein by reference, and the SOPs (as 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

3

 

defined in Section 2.13). The Manufacturing Agreements for
manufacturing Fraction IV-I/PEG Paste into the Column Eluate and Fraction IV-I
Paste into ATM shall be renewed annually, consistent with the Term of this
Agreement, with each such renewal deemed attached hereto as Exhibit F and Exhibit G, respectively, and
incorporated herein by reference. In the event of a conflict between the
provisions of this Agreement and the provisions of either of the Manufacturing
Agreements, the provisions of this Agreement shall prevail. Bayer shall
maintain all records as are necessary and appropriate to demonstrate compliance
with cGMPs and the Regulations. In no event shall any change to the batch
production records be implemented until Bayer has received written approval
from Purchaser which approval will not be unreasonably withheld. Bayer shall
make no changes in the production equipment, production procedures, or testing
methods existing as of the date of this Agreement. without providing reasonable
notice to Purchaser in advance of the change and obtaining Purchaser’s prior
written consent which consent will not be unreasonably withheld.

 

2.6           Yield.
The standard expected yield of Products based on kilograms and potency of the
Inputs and alpha-1 potency (“Expected Yield”), and the calculation method used to
determine such Expected Yield, shall be set forth on Exhibit H, which shall be attached
hereto and incorporated herein by reference (the “Yield Calculation”). The actual yield of
Column Eluate (“Actual
Yield”) and the Expected Yield shall be reconciled by Bayer
quarterly within thirty (30) days of each January 1, April 1, July 1 and
October 1, and the results thereof shall be promptly reported to Purchaser.
Upon mutual agreement of the Parties, the Expected Yield shall be appropriately
adjusted. As soon as practicable following the Effective Date, the Parties
shall mutually agree upon, in writing, the effect that any variance between
Expected Yield and Yield Calculation may have on price.

 

During any rolling four quarter period of the Term, if the Actual Yield
fails to meet the Expected Yield, then Bayer shall compensate Purchaser for
that amount of Inputs used in the processing attributable to the lower yield,
and if the Actual Yield exceeds the Expected Yield, then Purchaser shall
compensate Bayer for that amount of Inputs used in processing attributable to
the higher yield, in each case at a rate of one hundred fifteen percent (115%)
of the Input Replacement Value (as defined in Section 2.13) per kilogram of
Inputs.

 

[***]

 

Without limiting the foregoing, Purchaser may at its election provide
additional Inputs to Bayer to compensate for any variance between Expected Yield
and Actual Yield so that Products may be processed in amounts meeting the
quantity specified in the Binding Production Forecast; provided, however, that
any election by Purchaser not to provide such additional Inputs shall operate
to waive Purchaser’s rights under Section 9.4.

 

If Purchaser fails to provide Inputs which constitute Required Inputs
and which meet the Input Specifications for any reason (including Force
Majeure), then Bayer shall not be responsible for meeting the Expected Yield
computed pursuant to this Section 2.6 for as long as such failure continues and
for a period of forty-five (45) days after Purchaser resumes providing Inputs
which constitute Required Inputs and which meet Input Specifications. If
Purchaser does not provide Inputs which 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

4

 

constitute Required Inputs and which meet the Input Specifications for
any reason, including Force Majeure, for a consecutive period of six (6)
months, then the Parties shall negotiate in good faith for a period of three
(3) months to amend this Agreement as to direct costs of Bayer as a result of
Inputs that do not constitute Required Inputs or do not meet Input
Specifications. If the Parties are unable to reach agreement to amend this
Agreement during the Initial Term, then the matter shall be resolved in
accordance with Section 12.9. If the Parties are unable to reach agreement to
amend this Agreement during any term after the Initial Term, then Bayer may, at
its sole option, terminate this Agreement for cause pursuant to Section 4.1
hereof.

 

2.7           Samples.
Bayer shall provide to Purchaser adequate samples of ATIII prior to the
shipment of ATIII (“Product
Samples”) and Purchaser shall provide to Bayer adequate samples
of the Inputs along with the shipment of Inputs (“Input Samples,” together with the
‘Product Samples, the “Samples”)
for testing by Purchaser and Bayer, respectively, to determine the Samples’
compliance with the Product Specifications or Input Specifications, as
applicable. Bayer and Purchaser shall supply the other Party with Samples
according to a schedule (as may be amended from time to time) to be mutually
agreed upon by the Parties in writing. Each of Purchaser and Bayer shall use
its commercially reasonable efforts to test the Samples within a period of
twenty (20) days. from such Party’s receipt of such Samples. The Parties shall
use commercially reasonable efforts to expedite the testing of such Samples.
Notwithstanding the foregoing, if after accepting a shipment of Products or
Inputs, Purchaser or Bayer, respectively, subsequently discovers latent defects
(including without limitation, nonconformance with Product Specifications or
Input Specifications, as applicable) attributable to the other Party’s
performance under this Agreement not reasonably discoverable at the time of
delivery, such Party may revoke its acceptance of such shipment of Products or
Inputs, respectively, by giving written notice to the other Party as soon as
practicable after discovering such defects, and in such event, such Products or
Inputs shall be considered Nonconforming Products or Nonconforming Inputs, as
the case may be, and the provisions of Section 6.1 below shall apply.

 

2.8           Testing.
With respect to each shipment of Products to be shipped to Purchaser, Bayer
shall test such Products to ensure compliance with the Product Specifications.
Bayer shall include a certificate of analyses with each shipment of Products
disclosing the results of such testing and showing conformance with the Product
Specifications.

 

2.9           Order
and Availability. Purchaser shall place an order for Products reflecting
the aggregate amount of Products in the initial Binding Production Forecast
once Purchaser has determined, based on applicable test results obtained by it,
that the relevant Product Samples have met the Product Specifications. With
each subsequent Binding Production Forecast, Purchaser shall deliver an order
reflecting the aggregate Column Eluate ordered for the sixth month of the Column
Eluate Binding Production Forecast and the aggregate ATIII ordered for the
sixth month of the ATIII Binding Production Forecast (in each case, an “Order”). The Orders
shall specify delivery dates for the Products. Shipments of Products shall be
scheduled by the Parties consistent with the Orders and the Binding Production
Forecasts. The Parties shall cooperate to ensure that the Products to be
purchased by Purchaser are ordered, and the Inputs to be provided by Purchaser
are provided, in a manner so as to allow Bayer to produce such Products
efficiently, without material swings in volume over. the course of any twelve
(12) month period. The Parties shall cooperate to match the batch size of the
Orders with the Inputs 

 

5

 

provided by Purchaser, taking into consideration, without limitation,
Bayer’s normal production lot size.

 

2.10         Shipments.
Subject to an adequate supply of Required Inputs being supplied by Purchaser
(pursuant to Sections 2.1 and 2.3 herein), Bayer agrees that it shall provide
Products in conformity with the delivery schedule provided by Purchaser to meet
those Orders issued by Purchaser, provided that in no event shall Bayer be
required to provide Products in excess of any Binding Production Forecast.
Unless otherwise agreed by the Parties, provided that Purchaser timely provides
the Inputs and places the Orders, time is of the essence for the delivery of
Products in accordance with the Orders. Bayer shall include copies of
production records with each shipment. Purchaser shall be responsible for
making all necessary shipping arrangements for Inputs and Products. Risk of
loss for the Inputs and Products in transit shall lie with Purchaser. All
Inputs and Products shall be delivered F.O.B. Bayer Facility. All financial
arrangements for shipping and handling of Inputs and Products shall be the
responsibility of Purchaser.

 

2.11         Contract
Review and Onsite Personnel. Commencing as soon as practicable following
the Effective Date and thereafter on or about the first day of each month
during the Term, the manufacturing representative of each Party shall hold
contract review meetings, in person or via telephone, to discuss yields,
Product delivery schedules, quality issues, and other issues pertinent to this
Agreement. At least three (3) business days prior to each monthly meeting, each
Party shall deliver to the other Party a written report regarding the issues to
be discussed at such meeting. In addition to the monthly meetings, a senior
manager of each Party shall meet (either in person or via telephone) on a
quarterly basis and hold informal discussions on a weekly basis regarding each
Party’s progress with respect to this Agreement. At the expense of Purchaser,
Purchaser shall be entitled, in its sole discretion, to have a designated
employee (which designated employee may be different persons from time to time)
of Purchaser present at the Bayer Facility for the purposes of monitoring the
Manufacturing Services and quality control of the Products. Such designated
employee shall (a) have access to all areas of the Bayer Facility relating to
Manufacturing Services, (b) comply with all safety and health laws,
regulations, policies and procedures applicable to personnel of Bayer at the
Bayer Facility and (c) remain an employee of Purchaser and continue to receive
all compensation and benefits directly from Purchaser or its affiliates.
Notwithstanding anything to the contrary in the foregoing, the presence of a
Purchaser designated employee at the Bayer Facility and any action taken by
such employee in no way impairs or waives any right or remedy Purchaser may
otherwise have pursuant to the terms of this Agreement.

 

2.12         Bayer
Processing. Bayer shall process the Inputs on a first in-first out basis to
the extent possible.

 

2.13         Risk
of Loss. The Parties agree that Purchaser shall bear the risk of loss for
Inputs until the shipment is received in acceptable condition in accordance
with Purchaser’s Standard Operating Procedures (as in effect as of the Effective
Date and amended from time to time upon mutual agreement, and any replacements
or successors thereto, “SOPs”)
from the common carrier at the Bayer Facility. The risk of loss for the Inputs
shall be borne by Bayer after the shipment of the Inputs is delivered to
Bayer’s Facility by the common carrier and until delivery of Products is
tendered to Purchaser through the placement of the Products in the care,
custody 

 

6

 

and control of a common carrier under contract to Purchaser for
transporting to the Purchaser’s Facility or such other location designated by
Purchaser. Unless the Parties enter into a separate agreement obligating Bayer
to provide storage for the Products, Purchaser shall bear the risk of loss for
the Products after the Products are placed in the custody of the common carrier
at the Bayer Facility. In the event of the loss of any Inputs provided by
Purchaser for the production of the Products while in Bayer’s possession, which
is non-recoverable by rework or which results in the loss of the Products in
process or to be processed from such lost Inputs (a “Catastrophic Loss”),
Bayer shall compensate Purchaser for the damages attributable to the
Catastrophic Loss equal to [***]
per kilogram as adjusted pursuant to Section 3.2 hereof (the “Input Replacement Value”)
of the Inputs, for the Inputs so lost. Any Catastrophic Loss shall not be used
in the determination of Actual Yields.

 

2.14         Debarment.
Bayer certifies it will not use in any capacity the services of any person,
including any firm or individual, that has been debarred or is subject to
debarment under the Generic Drug Enforcement Act of 1992, amending the Food
Drug and Cosmetic Act at 21 USC 335a(a) or (b). Bayer agrees to notify
Purchaser promptly in the event any person providing services to Bayer under
the scope of this Agreement is debarred or becomes subject to debarment.

 

2.15         Cooperation
of the Parties. Purchaser shall inform Bayer promptly of any problems that
could reasonably be expected to prevent Purchaser from providing timely
deliveries of the Inputs to Bayer for process in accordance with this Article
2. Similarly, Bayer shall inform Purchaser promptly of any problems that could
reasonably be expected to prevent Bayer from processing the Inputs for the
production of the Products. The Parties shall cooperate in resolving such
problems relating to the manufacture and supply of the Products under this
Agreement. In recognition of the fact that Purchaser’s business is dynamic and
evolving based on market demand, regulatory approvals and other factors, Bayer
shall in good faith, but subject to the terms of this Agreement, use
commercially reasonable efforts to seek to accommodate any reasonable request
by Purchaser to manufacture quantities of Products in excess of Bayer’s
obligations hereunder; provided, however, that Bayer shall have no liability as
a result of any failure to accommodate such requests despite such efforts. The
Parties shall use their commercially reasonable efforts to coordinate
maintenance outages and shut-downs of the Bayer Facility and the Purchaser’s
Facility, which coordination could include making temporary changes to the
Binding Production Forecast. For purposes of clarification, this Section 2.15
does not diminish or expand the Parties’ respective obligations to supply and
purchase Products in accordance with any Binding Production Forecast set forth
in Section 2.4.

 

2.16         Records.
Bayer shall maintain production records and other records required by cGMPs and
the Regulations for such time periods referenced thereby. Bayer shall make such
records available to Purchaser for Purchaser’s inspection promptly following a
written request by Purchaser.

 

ARTICLE 3 PRICE AND PAYMENT

3.1           Charge
for Manufacturing Services. During the Term of this Agreement, Purchaser
shall pay the applicable price for the Products set forth in Exhibit I, attached hereto and
incorporated herein by reference, as may be adjusted from time to time pursuant
to Section 3.2. The price of 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

7

 

the Products shall be F.O.B. Bayer Facility. All payments hereunder
shall be made in U.S. dollars.

 

3.2           Adjustment
to Prices. [***]

 

(ii)           The
price shall be further subject to adjustment in accordance with Sections 5.4
and 8.1.

 

3.3           Price
Adjustment Calculation. On October 1st of each calendar year or
as soon thereafter as possible, Bayer shall provide for Purchaser’s review and
approval the computation of the Price Adjustment (as determined in accordance
with Section 3.2(i) above) to be applied in the following calendar year, and
the methodology used in making such computation. Such adjustment shall be final
and binding in the absence of manifest error.

 

3.4           Payments.
Bayer shall deliver to Purchaser at the address set forth in Section 12.3 an
invoice for shipments of Products to Purchaser as, the same is shipped. Each
invoice shall reflect the actual quantity of the Products shipped and the price
thereof as computed in accordance with Section 3.1, The amount invoiced by
Bayer and payable by Purchaser during each Binding Production Forecast period
will not be less than that charge associated with the Binding Production
Forecast as computed in accordance with Section 3.1, unless the actual amount
of Products delivered is less than the Binding Production Forecast due to
Bayer’s failure to perform its obligations under this Agreement. Within thirty
(30) days following receipt of each invoice, Purchaser shall pay to Bayer the
amount specified in such invoice.

 

3.5           Payment
Disputes. All billing and payment disputes between the Parties shall be
resolved in accordance with Section 12.9 below.

 

ARTICLE 4 EARLY TERMINATION

4.1           Termination
for Cause. If either Party commits a substantial violation of any material
provision of the Agreement (which means (i) in the case of Purchaser,
nonpayment of amounts owing to Bayer in accordance with Section 3.4, failure to
supply Inputs as provided in Section 2.6, or any other material breach by
Purchaser of any representation, warranty, covenant or performance obligation
under this Agreement and (ii) in the case of Bayer, any material breach of any
representation, warranty, covenant or performance obligation under this
Agreement (other than breach of its obligation to deliver Products under this
Agreement, any such breach to be governed exclusively under Section 9.4
hereof)), the other Party may, without prejudice to any other right or remedy,
and after giving the breaching Party sixty (60) days’ written notice of the 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

8

 

breach, terminate the Agreement. This Agreement shall not be so
terminated if the breaching Party has cured the breach, or submitted a plan for
curing breach reasonably acceptable to the non-breaching Party within sixty
(60) days after the non-breaching Party’s notice. If the breaching Party fails
to cure the breach as set forth in the aforementioned plan in accordance with
the deadlines set forth therein, the non-breaching Party may terminate this
Agreement without further notice. The non-breaching Party shall have the right
to recover all direct damages and losses arising as a result of any such
material breach, including lost profits but not including consequential
damages, provided that any such recovery shall be reduced by the amount that
such non-breaching Party actually recovers under any insurance it maintains.

 

Other Termination Provisions. By Bayer if
Purchaser or by Purchaser if Bayer:

 

(i)             admits in writing
that it is unable to pay its debts as they become due;

(ii)            starts a proceeding,
or indicates its acquiescence to a proceeding started by another, relating to
it under any bankruptcy, reorganization, rearrangement, insolvency,
readjustment of debt, dissolution, liquidation or similar law;

(iii)           makes an assignment for
the benefit of creditors;

(iv)          consents to the
appointment of a receiver, trustee or liquidator for a substantial part of its
property;

(v)           files, or has filed
against it, a petition in bankruptcy, reorganization, rearrangement or
insolvency which, if filed against it, is not dissolved or dismissed within
ninety (90) days after filing; or

(vi)          has entered against it
an order by a court of competent jurisdiction appointing a receiver, trustee or
liquidator for it or a substantial part of its property, or approving its
dissolution or termination, and if not consented to or acquiesced in by such
Party, such order is not vacated or set aside or stayed within ninety (90)
days.

Notwithstanding anything to the contrary in the foregoing, no Party
shall take or cause to be taken any action relating to the voluntary
liquidation or dissolution of such Party.

 

4.2           Effect
of Termination. In the event of termination of this Agreement, (i) Purchaser
shall immediately cease delivery of all Inputs under this Agreement, (ii) Bayer
shall promptly cease production of the Products and shall deliver any Products
manufactured prior to the effective date of termination but not yet delivered,
(iii) Bayer shall prepare and submit to Purchaser an invoice for all Products
shipped by Bayer to Purchaser which at the time of the effective date of
termination were not paid for by Purchaser, and (iv) Bayer shall return to
Purchaser all Inputs that are in Bayer’s possession or en route to Bayer at the
time of such termination which return shall be at the sole cost and expense of
the Party whose breach of this Agreement resulted in the termination of the
Agreement. Purchaser shall within thirty (30) days following receipt of the
invoice referred to in subclause (iii) of this Section 4.3 pay the full amount
of such invoice and all other sums owed to Bayer; provided, however, that if
the aggregate total of the Orders placed by Purchaser prior to the effective
date of such termination does not meet the Required Quantity for the then
current calendar year and in the event that Bayer terminates this Agreement in 

 

9

 

accordance with Section 4.1 due to Purchaser’s breach hereof, Purchaser
shall be obligated to pay amounts associated with the Products to be delivered
under the then current Binding Production Forecast and, at Purchaser’s sole
discretion, Bayer shall be obligated to deliver such Products.

 

4.3           Remedies.
The rights of a Party to this Agreement to recover monetary damages from the
other Party to this Agreement with respect to termination of this Agreement are
exclusively set forth in this Article 4. Each Party shall have such
non-monetary rights and remedies provided under this Agreement or under law or
in equity for breaches of this Agreement, but limited to the remedy of specific
performance.

 

4.4           Survival.
In the event of any termination or expiration of this Agreement, each of the
provisions of Articles 6, 7, 8, 9, 10, 11, 12 and Sections 2.5, 2.6, 2.7, 2.8,
2.10, 2.13, 2.14, 2.16, 3.5, 4.1, 4.3, 4.4, 4.5, 5.1, 5.3 and 5.4 shall survive
as long as any such provision remains applicable, provided that Article 9 shall
survive indefinitely, unless a shorter period for survival is provided in any
such Article or Section.

 

ARTICLE 5 COMPLIANCE

5.1           Compliance
with Regulations. In the performance of its obligations under this
Agreement, each Party shall comply in all material respects with all applicable
laws, requirements, regulations, guidelines, licenses and directives, including
those in any Regulatory Approval of any Regulatory Authority (including without
limitation, current Good Manufacturing Practices (“cGMPs”) as defined in
national and international accepted GMP compendia including PIC/C and WHO GMP
Guide) including all specifications and procedures for plasma sourcing, plasma
testing, and in process testing and all regulations, specifications, and
procedures contained therein (collectively, the “Regulations”). Each Party shall comply
with all Regulations that become effective after the Effective Date within the
timeframes required by such Regulation or applicable Regulatory Authority.
Bayer shall not amend or replace any SOPs related to the Manufacturing Services
without providing reasonable notice to Purchaser in advance of the change and
obtaining Purchaser’s prior written consent. Purchaser shall not amend or
replace any SOPs related to the Inputs without providing reasonable notice to
Bayer in advance of the change and obtaining Bayer’s prior written consent.
Each Party shall use commercially reasonable efforts to provide such consent as
soon as reasonably practicable with -the understanding that Bayer is under no
obligation to provide any such consent if Purchaser’s proposed change would
adversely affect Bayer’s performance of the Manufacturing Services.
Notwithstanding the foregoing, until the second anniversary of the Effective
Date, Purchaser shall not be liable to Bayer for, or considered in breach of
this Agreement as a result of, any noncompliance or failure to comply with any
Regulations to the extent such noncompliance or failure was in existence at the
time of Closing (as defined in the Contribution Agreement); provided, however,
that all other obligations of Purchaser contained herein shall remain in full
force and effect at all times from and after the Effective Date. For purposes
of this Agreement (i) “Regulatory
Approvals” shall mean all licenses, approvals, permissions, or
consents required for the manufacture, processing, distribution or sale of the
Products and (ii) “Regulatory
Authority  and
Regulatory Authorities” shall mean the FDA and any successor
agency and all other local, state, federal, or foreign governmental authorities
with authority to grant or deny the 

 

10

 

necessary Regulatory Approvals or to regulate the manner of means by
which the Products are manufactured, processed, distributed, or sold.

 

5.2           Audit.
(i) Each Party shall have the right, on reasonable written advance notice (to
the extent practicable, not less than one (1) week advance notice), and during
normal business hours, to inspect and audit the other Party’s facilities, SOPs,
production, operations, testing, storage and books and records to confirm
compliance with Section 5.1 and the other Party’s compliance with the terms and
conditions of this Agreement, provided that such inspection or audit does not
unreasonably interfere with the conduct of business of such other Party. Each
Party shall use its commercially reasonable efforts to accommodate any
reasonable request made by the other Party to inspect such facility. Each Party
shall respond in writing to the other Party regarding any items of
noncompliance identified by the other Party during such inspections or audits
within fifteen (15) days of the other Party’s notice thereof and shall develop
a plan, reasonably satisfactory to the other Party, to remedy any such items of
noncompliance within sixty (60) days of notice thereof, and shall remedy such
items of noncompliance as set forth in such plan, the failure of which shall
entitle the other Party to terminate this Agreement in accordance with Section
4.1 hereof.

 

5.3           Regulatory
Filings. Each Party shall promptly accommodate all requests made by any
Regulatory Authority (as defined in Section 5.1) to audit such Party’s
facilities. Both Parties shall have the right to review, during the Term and
for a period of five (5) years thereafter, all audit findings or notices of
Regulatory Authorities as such may, directly or indirectly, bear upon the
Inputs, the Products or each Party’s obligations under this Agreement. Each
Party shall develop. and provide to the other Party a plan, reasonably
satisfactory to the other Party, to remedy, and shall remedy, any deficiencies
identified as a result of a regulatory inspection in the timeframes provided in
the applicable inspection report or the applicable Regulations. Bayer shall
promptly notify Purchaser (i) after Bayer becomes aware of any Regulatory
Authority inspection of the Bayer Facility and (ii) after Bayer receives notice
from a Regulatory Authority of any observation or regulatory action, such as a
warning letter. Bayer shall promptly provide a copy of any audit finding with
Bayer’s corrective action response to Purchaser for items that, directly or
indirectly, relate to the Manufacturing Services or any of Bayer’s obligations
under this Agreement. Purchaser shall notify Bayer (i) at the time Purchaser
becomes aware of any Regulatory Authority inspection of the Purchaser’s
Facility and (ii) at the time Purchaser receives notice from any Regulatory
Authority of any observation or regulatory action, such as a warning letter.
Purchaser shall promptly provide a copy of any audit finding with Purchaser’s
corrective action response to Bayer for items that, directly or indirectly,
relate to the Inputs or the Products or any of Purchaser’s obligations under
this Agreement.

 

5.4           Regulatory
Approvals. Bayer is solely responsible for obtaining and maintaining all
necessary Regulatory Approvals from all Regulatory Authorities necessary for
the performance of the Manufacturing Services at the Bayer Facility. Purchaser
is solely responsible for obtaining and maintaining all Regulatory Approvals
necessary to further process, distribute or sell the Products. Each Party shall
upon request and as reasonably necessary provide all documents or information
requested by the other Party to support the other Party’s efforts to obtain,
maintain, or defend Regulatory Approvals to manufacture, further 

 

11

 

process, distribute or sell the Products and/or will modify its
operations or facilities as required to permit the other Party to obtain,
maintain, or defend necessary Regulatory Approvals to manufacture, further
process, distribute and sell the Products; provided if the modifications to
operations or facilities requested by a Party are modifications which would
require the other Party to change the manner of operations existing as of the
date of this Agreement or to add facilities not in place as of the date of this
Agreement, such Party will reimburse the other Party’s reasonable direct costs
in making such modifications and the Parties shall engage in good faith
negotiations to adjust the price set forth in Section 3.1 to reflect the
increase or decrease of ongoing costs of processing the Products hereunder
resulting from any such modifications; provided further that if the Parties
cannot reach an agreement to adjust the price pursuant to this Section 5.4
despite such good faith negotiations, (i) if the requested modifications will
affect only the Product operations of such Party at either the Bayer Facility
or the Purchaser’s Facility, as applicable, the matter shall be resolved in
accordance with Section 12.9, or (ii) if the requested modifications will, in
the sole discretion of the affected Party, adversely affect in any material
manner other operations of such Party at either the Bayer Facility or the
Purchaser’s Facility, as applicable, separate from the Product operations of
such Party at either the Bayer Facility or the Purchaser’s Facility, as
applicable, such Party shall not be required to make any such modifications
until the Parties reach such agreement; provided further such Party will have
no obligation to reimburse the other Party for any maintenance, repair or
replacement of existing facilities or for the substitution of their equivalent
or for any increases in costs associated with the other Party’s conduct of operations
in a fashion similar to or equivalent to the manner in which those operations
were being conducted in the absence of such request as of the date of this
Agreement.

 

ARTICLE 6 NONCONFORMING
PRODUCT AND RECALLS

6.1           Nonconforming
Product. (i) Purchaser shall provide Bayer with the identification number
of any plasma unit that was pooled and manufactured into a batch or lot of
Nonconforming Inputs delivered to Bayer. In the event that Purchaser provides
Inputs that do not meet the Regulations or do not conform to the Input
Specifications, or contain latent defects, or that have not been manufactured,
processed, distributed, transported, disposed, stored, tested or otherwise
handled in accordance with applicable SOPs, the Input Specifications, cGMPs and
the Regulations (“Nonconforming
Inputs”), Purchaser shall remain obligated to pay Bayer for
those Manufacturing Services performed by Bayer with such Nonconforming Inputs
prior to such later time, if any, as Purchaser notifies Bayer that such Inputs
are Nonconforming Inputs or Purchaser achieves the Required Quantity. To the
extent Nonconforming Inputs have been processed, then Purchaser will reimburse
Bayer based on the percentage of processing completed. Nonconforming Inputs
shall, at the option of Purchaser, be destroyed by Bayer (and a certificate of
destruction shall be promptly provided by Bayer to Purchaser) or returned to
Purchaser. Purchaser shall reimburse Bayer for the reasonable costs of
destruction or return of all Nonconforming Inputs. At Purchaser’s sole
election, Purchaser may provide additional Inputs to Bayer for processing into
Products to replace Non-Conforming Inputs so as to achieve the Required
Quantity.

 

(ii)           In
the event that Bayer supplies Products that do not meet the Regulations or do
not conform to the Product Specifications, or contain latent defects, or that
have not been manufactured, processed, distributed, transported, disposed,
stored, tested or otherwise handled in accordance with applicable SOPs, the
Product Specifications, cGMPs and the Regulations, (“Nonconforming Products”)
and such Nonconforming Products are not attributable to Nonconforming Inputs,
then (i) Bayer shall, at no cost to Purchaser, and as soon as reasonably 

 

12

 

feasible, replace such Nonconforming Product with an equivalent amount
of conforming Product to the extent Purchaser elects to provide additional
Inputs to Bayer and (ii) such Nonconforming Products shall at the option of
Purchaser be destroyed by Bayer (and a certificate of destruction shall be
promptly provided by Bayer to Purchaser) or returned to Purchaser. Bayer shall
reimburse Purchaser for the reasonable costs of destruction or return of all
Nonconforming Products plus the Input Replacement Value of any additional
Inputs provided by Purchaser.

 

(iii)          In
the event that the Parties are unable to agree as to whether Nonconforming
Inputs resulted in a Nonconforming Product, then a mutually selected
independent third party laboratory shall perform testing and provide results
thereof to the Parties within thirty (30) days of receiving the Inputs and
Products for testing for purposes of making such determination. The Parties
shall share equally the costs of such testing.

 

6.2           General
Requirements. Purchaser shall maintain accurate records of the quantities
of the Inputs shipped to Bayer and Bayer shall maintain accurate records of all
Products derived from such Inputs.

 

6.3           Distribution and Use
Records.

(i)             Purchaser shall
maintain and give Bayer access upon advance notice and at reasonable times, to,
for a period of not less than fifteen (15) years from production, donor records
and test results with respect to each unit of the Inputs delivered to Bayer.
Such records and results shall be maintained such that they can rapidly and
unequivocally be accounted for and made available to Bayer within fourteen (14)
days from the date of request.

(ii)            Records of the use of
each lot of the Inputs delivered to Bayer shall be maintained by Bayer for a
period of not less than fifteen (15) years from the date of delivery. Such
records shall be maintained such that the use of each lot of the Inputs can be
rapidly and unequivocally accounted for and the Products into which such Inputs
were processed, identified and made available to Purchaser within fourteen (14)
days from the date of request. Purchaser shall assist Bayer in identifying,
tracking and controlling the use of any Inputs identified in post-donation
information as contaminated or otherwise unsuitable for processing into
Products.

(iii)           Records regarding the
testing, storage, distribution and disposal of the Products shall be maintained
by Purchaser for such period required by the Regulations.

6.4           Adverse
Events. Purchaser shall record and investigate all reports of adverse
events in which Products manufactured from the Inputs have been implicated. If
Purchaser determines that a Product has caused adverse reactions as a result of
such Product being manufactured from Inputs, Purchaser shall immediately notify
all Regulatory Authorities as required by the Regulations. Purchaser shall
promptly notify Bayer of any such adverse events and shall provide Bayer with
copies of all documents provided by Purchaser to Regulatory Authorities with
respect thereto.

 

6.5           Customer
Notification of Adverse Reactions. In the event that during the course of a
preliminary investigation related. to a report of any serious adverse reaction
associated with the Products, Purchaser obtains preliminary evidence indicating
that, according to indications and dosage, the Inputs used in the manufacture
of the Products may have caused such specific 

 

13

 

adverse reaction, each Purchaser customer that received any such
Products shall be notified by Purchaser and cautioned that any unused
containers of the suspect lots should be withheld from use, pending the outcome
of more definitive investigations and evaluations, with a copy of such notice
to the applicable Regulatory Authority, if required. Purchaser shall promptly
provide Bayer with a copy of such notice. Any and all of the foregoing actions
will be executed with the concurrence of all relevant Regulatory Authority, to
the extent required by law.

 

6.6           Withdrawals
and Recalls. Purchaser shall make all contacts with relevant Regulatory
Authority and shall be responsible for coordinating all activities in
connection with any recall or withdrawal of any Product. In the event that
Bayer believes a recall or withdrawal of a Product may be necessary or appropriate,
Bayer shall promptly notify Purchaser in writing. In the event that Purchaser
initiates a recall or Product withdrawal, Purchaser shall promptly notify
Bayer.

 

6.7           Customer
Complaints. Bayer and Purchaser will cooperate, according to policies
mutually determined by the Parties in writing, in the reporting, investigation
and evaluation of customer complaints.

 

6.8           Responsibility.
In the event that any market withdrawal, recall or third party return of any
Product results from Bayer’s supply of Nonconforming Product, then Bayer shall
assume the claims and costs associated with such withdrawal, recall or return
and the destruction of implicated Products to the extent attributable to
Bayer’s Nonconforming Product. Notwithstanding the foregoing, Bayer shall not
be liable for any market withdrawals, recalls or third party returns caused by
Nonconforming Inputs supplied by Purchaser.

 

6.9           Deviation
Report. (i) If during the manufacture, processing, storage, distribution,
testing, transport, disposal or other handling of the Products by Bayer there
arises a result that is classified as either a Type I Incident or a Type II
Incident (as defined below), then Bayer shall prepare within seven (7) days
following the discovery of such deviation a written report detailing such
deviation (a “Deviation
Report”) and promptly send to Purchaser such Deviation Report
prior to Bayer’s delivery of the Products which is the subject of such report.
If Purchaser rejects a shipment of the Products based on a Deviation Report, it
shall promptly notify Bayer, such Products shall be considered Nonconforming
Products and the provisions of Section 6.1 shall apply. For purposes of this
Agreement, a “Type I
Incident” shall be defined as an unexpected result that has
potential serious impact on product safety, identity, strength, quality,
purity, efficacy or manufacturing/testing process. Examples of Type I Incidents
include final product sterility and stability failure, media fill failure,
pyrogen specification exceeded for bulk or final container and inadequate viral
inactivation process. For purposes of this Agreement, a “Type II Incident”
shall be defined as an unexpected result that has the potential to affect
product safety, identity, strength, quality, purity, efficacy, or manufacturing/testing
process. Examples of Type II Incidents include clean steam exceeding action
level for LAL and Presterile in-process bioburden exceeding action level.

 

(ii)           If
during the manufacture, processing, storage, distribution, testing, transport,
disposal or other handling of the Inputs by Purchaser there arises a result
that is classified as either a Type I Incident or a Type II Incident, then
Purchaser shall prepare within seven (7) days following the discovery of such
deviation a Deviation Report and promptly send to Bayer such Deviation Report
prior to Purchaser’s delivery of the Inputs which is the subject of such
report. If Bayer 

 

14

 

rejects a shipment of the Inputs based on a Deviation Report, it shall
promptly notify Purchaser, such Inputs shall be considered Nonconforming Inputs
and the provisions of Section 6.1 shall apply.

 

ARTICLE 7 CONFIDENTIALITY

7.1           Confidentiality
Obligations. All information provided by one Party to the other Party in
connection with this Agreement (including without limitation, the Product
Specifications and Input Specifications and forecasts provided by Purchaser)
shall be maintained in strict confidence by the receiving Party. Such
information shall remain the property of the providing Party, and the receiving
Party shall not make use of any such information except for the purposes for
which it was provided. At the termination of this Agreement, the receiving
Party shall promptly return to the providing Party any physical embodiments
(including copies) of any such information. Each Party agrees to keep
confidential the existence of this Agreement, as well as all of its terms and
conditions; provided that if a public announcement or disclosure is required by
law, rule, regulation, court order, subpoena, interrogatory or other discovery
request (including without limitation applicable securities laws or stock
exchange regulations), and subject to Section 7.2(v), the Party required to
make the public announcement or disclosure shall be permitted to make such
disclosure and shall provide prompt prior written notice of such requirement to
the other Party, and the Parties shall thereafter negotiate in good faith, to
the extent appropriate and feasible, the contents of the public announcement or
disclosure.

 

7.2           Exceptions.
The covenants of the receiving Party contained in Section 7.1 shall not apply
to information which: (i) is already in the public domain at the time of
disclosure; (ii) becomes part of the public domain through no action or
omission of the receiving Party after disclosure to the receiving Party; (iii)
is already known to the receiving Party on a non-confidential basis at the time
of disclosure, as evidenced by the receiving Party’s written records, except
for information that was known to Bayer prior to the Effective Date; (iv) has
been or is disclosed to the receiving Party in good faith by a third party who
was or is not, at the time of disclosure, under any obligation of confidence to
the other Party hereto at the time the third party disclosed such information;
or (v) is required to be disclosed by law, provided that the receiving Party
shall cooperate with the disclosing Party (at the disclosing Party’s expense)
in obtaining any available protection for such information to be disclosed.

 

7.3           Term
of Obligations. This Article 7 shall survive termination of this Agreement
for a period of five (5) years.

 

ARTICLE 8 WARRANTIES AND
COVENANTS

8.1           General.
(i) Bayer represents and warrants as of the time immediately prior to the
Closing (as defined in the Contribution Agreement) that the manufacture,
processing, testing, distribution, transport, storage, disposal and other
handling of the Inputs by Bayer until delivery to and processing at the Bayer
Facility (i) conformed to the SOPs relating to the Inputs, the Input
Specifications, cGMPs and the Regulations and (ii) were free from defects in
materials and 

 

15

 

workmanship and were not adulterated or misbranded within the meaning
of applicable Regulations.

 

(ii) Purchaser represents and warrants that the manufacture,
processing, testing, distribution, transport, storage, disposal and other
handling of the Inputs by Purchaser until delivery to and processing by Bayer
shall (i) conform to the SOPs relating to the Inputs, the Input Specifications,
cGMPs and the Regulations and (ii) be free from defects in materials and
workmanship and shall not be adulterated or misbranded within the meaning of
applicable Regulations. Purchaser shall deliver a certificate of analyses with
each shipment of the Inputs specifying the results of its testing and analysis
to show conformance with the Input Specifications. Similarly, Bayer represents
and warrants that the Manufacturing Services until the Products are delivered
to and processed by Purchaser shall (i) conform to the SOPs relating to the
Manufacturing Services, the Product Specifications, cGMPs and other Regulations
and (ii) be free from defects in materials and workmanship and shall not be. adulterated
or misbranded within the meaning of applicable Regulations. Either Party shall
be entitled to request the other Party to change the Input Specifications or
Product Specifications, as applicable, or SOPs where, in such Party’s sole
discretion, such change would benefit the production of the Products and the
other Party shall use commercially reasonable efforts to accommodate such
change; provided that the Party making such request will reimburse the other
Party the reasonable direct costs the other Party incurs in making any such
change; provided further that the Parties shall engage in good faith
negotiations to adjust the price set forth in Section 3.1 to reflect the
increase or decrease of ongoing costs of processing the Products hereunder resulting
from any such change; provided further that if the Parties cannot reach
agreement to adjust the price pursuant to this Section 8.1 despite such good
faith negotiations, then (i) if the requested modifications will affect only
the Product operations of such Party at either the Bayer Facility or the
Purchaser’s Facility, as applicable, the matter shall be resolved in accordance
with Section 12.9, or (ii) if the requested modifications will, in the sole
discretion of the affected Party, adversely affect in any material manner other
operations of such Party at either the Bayer Facility or the Purchaser’s
Facility, as applicable, separate from the Product operations of such Party at
either the Bayer Facility or the Purchaser’s Facility, as applicable, such Party
shall not be required to make any such modifications until the Parties reach
such agreement.

 

8.2           Intellectual
Property. (i) Bayer represents and warrants as of the time immediately
prior to the Closing (as defined in the Contribution Agreement) that the
manufacture, processing, testing, distribution, transport, storage, disposal
and other handling of the Inputs did not infringe the intellectual property
rights of any third party and that Bayer validly possessed all licenses to
third party intellectual property necessary or appropriate for the manufacture,
processing, testing, distribution, transport, storage disposal and other
handling of the Inputs.

 

(ii) During the Term of this Agreement, Purchaser represents and
warrants that the manufacture, processing, testing, distribution, transport,
storage, disposal and other handling of the Inputs pursuant to this Agreement
will not infringe the intellectual property rights of any third party; provided
that for purposes of making this representation and warranty Purchaser is
entitled to rely to the extent applicable on the representations and warranties
made by Bayer as of the Closing Date (as defined in the Contribution Agreement)
pursuant to the Contribution Agreement for so long as such representations and
warranties survive in the Contribution Agreement. During the Term of this
Agreement, Purchaser agrees to maintain at its sole cost and 

16

 

expense all licenses to third party intellectual property necessary or
appropriate for the manufacture, processing, testing, distribution, transport,
storage, disposal and other handling of the Inputs. Purchaser grants to Bayer a
fully paid, non-exclusive right and license to use Purchaser’s intellectual
property listed on Exhibit J
attached hereto and incorporated herein by reference solely for the purpose of
performing the Manufacturing Services, during the term of this Agreement. The
grant of this license in such intellectual property in no way provides Bayer
any rights in or authorization to use any other intellectual property of
Purchaser.

 

8.3           Representations and
Warranties.

(a)           Bayer
hereby represents and warrants to Purchaser that:

(i)             Due Organization,
Good Standing and Power. Bayer is a limited liability company duly
organized, validly existing and in good standing under the laws of the state of
Delaware. Bayer has all requisite corporate or other power and authority to own
or lease and to operate its assets and to conduct the business now being
conducted by it. Bayer is duly authorized, qualified or licensed to do business
as a foreign corporation or other organization in good standing in each of the
jurisdictions in which its ownership of property or the conduct of its business
requires such authorization, qualification or licensing, except where the
failure to have such authorization, qualification or licensing could not
reasonably be expected to have a material adverse effect on Bayer or on the
consummation of the transactions contemplated hereunder. Bayer has all requisite
corporate power and authority under Applicable Law and its Charter Documents to
enter into this Agreement and to perform its obligations hereunder and to
consummate the transactions contemplated hereby.

(ii)            Authorization and
Validity of Agreement. The execution and delivery of this Agreement by
Bayer and the consummation by it of the transactions contemplated hereby have
been duly authorized and approved by all necessary corporate action under
Applicable Law and the relevant Charter Documents on the part of Bayer and do
not require the approval of the stockholders of Bayer. This Agreement has been
duly executed and delivered by Bayer and constitutes the legal, valid and
binding obligation of Bayer enforceable against it in accordance with its terms,
except as that enforceability may be (i) limited by any applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting the
enforcement of creditors’ rights generally, (ii) subject to general principles
of equity (regardless of whether that enforceability is considered in a
proceeding in equity or at law) and (iii) limited by general principles of
Applicable Law regarding the enforceability of arbitral awards and judicial
decisions.

(iii)           Lack of Conflicts.
Neither the execution and delivery of this Agreement by Bayer or the
consummation by it of the transactions contemplated hereby, does or will (i)
conflict with, or result in the breach of any provision of, the Charter
Documents of Bayer or (ii) violate any Applicable Law or any permit, order,
award, injunction, decree or judgment of any Governmental Authority applicable
to or binding upon Bayer or to which any of its properties or assets is
subject.

17

 

(iv)           No
Consents. The execution, delivery and performance of this Agreement by
Bayer and the consummation of the transactions contemplated by this Agreement
do not require any Governmental Approval. No consent (other than Governmental
Approvals) will be required to he obtained by Bayer for the consummation of the
transactions contemplated by this Agreement.

 

(b)           Purchaser
hereby represents and warrants to Bayer that:

(i)             Due Organization,
Good Standing and Power. Purchaser is a corporation duly organized, validly
existing and in good standing under the laws of the state of Delaware.
Purchaser has all requisite corporate or other power and authority to own or
lease and to operate its assets and to conduct the business now being conducted
by it. Purchaser is duly authorized, qualified or licensed to do business as a
foreign corporation or other organization in good standing in each of the
jurisdictions in which its ownership of property or the conduct of its business
requires such authorization, qualification or licensing, except where the
failure to have such authorization, qualification or licensing could not
reasonably be expected to have a material adverse effect on Purchaser or on the
consummation of the transactions contemplated hereunder. Purchaser has all
requisite corporate power and authority under Applicable Law and its Charter
Documents to enter into this Agreement and to perform its obligations hereunder
and to consummate the transactions contemplated hereby.

(ii)            Authorization and
Validity of Agreement. The execution and delivery of this Agreement by
Purchaser and the consummation by it of the transactions contemplated hereby
have been duly authorized and approved by all necessary corporate action under
Applicable Law and the relevant Charter Documents on the part of Purchaser and
do not require the approval of the stockholders of Purchaser. This Agreement
has been duly executed and delivered by Purchaser and constitutes the legal,
valid and binding obligation of Purchaser enforceable against it in accordance
with its terms, except as that enforceability may be (i) limited by any
applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting the enforcement of creditors’ rights generally, (ii) subject to
general principles of equity. (regardless of whether that enforceability is
considered in a proceeding in equity or at law) and (iii) limited by general
principles of Applicable Law regarding the enforceability of arbitral awards
and judicial decisions.

(iii)           Lack of Conflicts.
Neither the execution and delivery of this Agreement by Purchaser or the
consummation by it of the transactions contemplated hereby, does or will (i)
conflict with, or result in the breach of any provision of, the Charter
Documents of Purchaser or (ii) violate any Applicable Law or any permit, order,
award, injunction, decree or judgment of any Governmental Authority applicable
to or binding upon Purchaser or to which any of its properties or assets is
subject.

(iv)          No Consents. The
execution, delivery and performance of this Agreement by Purchaser and the
consummation of the transactions contemplated by this Agreement do not require
any Governmental Approval. No consent (other than Governmental 

 

18

 

Approvals) will be
required to be obtained by Purchaser for the consummation of the transactions
contemplated by this Agreement.

ARTICLE 9 INDEMNITIES AND
DAMAGES

9.1           Indemnifications.
Purchaser hereby agrees to save, defend and hold Bayer and its affiliates and
its or their directors, officers, managers, employees, representatives,
consultants, stockholders, controlling persons and agents and each of the
heirs, executors, successors and assigns of any of the foregoing (together, the
“Bayer Group”)
harmless from and against any and all claims, suits, actions, liabilities,
expenses and/or losses, including punitive or exemplary damages and reasonable
attorneys’ fees and expenses (“Claims”) asserted by a person or entity other than a
member of the Bayer Group arising from any material breach of obligations under
this Agreement by the Purchaser Group (as defined below); provided that any
Claims for failure to deliver Inputs in accordance with the terms of this
Agreement shall be deemed a material breach. Bayer hereby agrees to save,
defend and hold Purchaser and its affiliates and its or their directors,
officers, managers, employees, representatives, consultants, stockholders,
controlling persons and agents and each of the heirs, executors, successors and
assigns of any of the foregoing (together, the “Purchaser Group”) harmless from and
against any and all Claims asserted by a person or entity other than a member
of the Purchaser Group arising from any material breach of obligations under
this Agreement by the Bayer Group; provided that failure to deliver Products in
accordance with the terms of this Agreement shall be governed exclusively under
Section 9.4 hereof Where a Claim arises directly or indirectly from acts or
omissions of both (i) the Purchaser Group and (ii) the Bayer Group, the obligation
of the Purchaser or Bayer to indemnify the other shall not exceed the extent of
the indemnifying party’s contribution to the harm giving rise to the Claim.

 

9.2           Indemnification
Process. Each party indemnified under the provisions of this Agreement,
upon receipt of written notice of any Claim or the service of a summons or
other initial legal process upon it in any action instituted against it for
which it may be entitled to indemnification pursuant to this Agreement, shall
promptly give written notice of such Claim, or the commencement of such action,
or threat thereof, to the Party from whom indemnity shall be sought hereunder;
provided, however, that the failure to provide such notice within a reasonable
period of time shall not relieve the indemnifying party of any of its
obligations hereunder except to the extent the indemnifying party is prejudiced
by such failure. Each indemnifying party shall be entitled at its own expense
to participate in the defense of such Claim or action, or, if it shall elect, so
long as it has acknowledged in writing to the indemnified party its
indemnification obligations hereunder, by written notice to the indemnified
party within twenty (20) days of receipt of notice of the Claim or action from
the indemnified party to assume such defense, in which event such defense shall
be conducted by counsel chosen by such indemnifying party (without prejudice to
the right of the indemnified party to fully participate at its own expense
through counsel of its own choosing) which counsel may be any counsel
reasonably satisfactory to the indemnified party against whom such Claim is
asserted or who shall be the defendant in such action, and such indemnified
party shall bear all fees and expenses of any additional counsel retained by it
or them, provided that the indemnifying party shall obtain the consent of the
indemnified party (which consent may be withheld in its sole discretion) before
entering into any settlement, adjustment or compromise of such Claims, provided
further that the indemnifying party may, without the consent of the indemnified
party, settle or compromise or 

 

19

 

consent to the entry of any judgment in any action involving only the
payment of money which includes as an unconditional term thereof the delivery
by the claimant or plaintiff to the indemnified party of a duly executed
written release of the indemnified party from all liability in respect of such
Claim or action which written release shall be reasonably satisfactory in form
and substance to the indemnified party. Notwithstanding the immediately
preceding sentence, if the named parties in such action (including impleaded
parties) include the indemnified and the indemnifying parties, and the
indemnified party shall have been advised by counsel that there may be a
conflict between the positions of the indemnifying party and the indemnified
party in conducting the defense of such action or that there are legal defenses
available to such indemnified party different from or in addition to those
available to the indemnifying party, then counsel for the indemnified party,
shall be entitled, if the indemnified party so elects, to conduct the defense
to the extent reasonably determined by such counsel to be necessary to protect the
interests of the indemnified party, at the expense of the indemnifying party.
If the indemnifying party shall elect not to assume the defense of such Claim
or action, such indemnifying party shall reimburse such indemnified party for
the reasonable fees and expenses of any counsel retained by it, and shall be
bound by the results obtained by the indemnified party in respect of such Claim
or action; provided, however, that no such Claim or action shall be settled
without the written consent of the indemnifying party (which consent shall not
be unreasonably withheld or delayed).

 

9.3           Insurance.
During the Term of this Agreement and for a period of at least two (2) years
following the expiration or earlier termination of this Agreement, each Party
shall maintain, at its sole cost and expense, general liability insurance,
including product liability coverage, with bodily injury, death and property
damage limits, in such amounts and with such scope of coverage as is consistent
with plasma industry standards. Each Party shall have its insurance carrier
furnish to the other Party certificates stating that all insurance required
under this Agreement is in force. Such certificates shall indicate any
deductible and self-insured retention and the effective expiration dates of the
policies. All certificates are to stipulate that the other Party shall be given
thirty (30) days written notice of all cancellation, non-renewal or material
changes in policy. Each Party shall be named as an additional insured on all
insurance policies obtained by the other Party in accordance with this Section
9.3. Each Party also agrees to waive and will require its insurers to waive all
rights of subrogation against the other Party, its directors, officers and
employees on all of the foregoing coverages.

 

9.4           Liquidated
Damages For Failure To Deliver Products. (a)  The Parties acknowledge that the anticipated
damages to Purchaser in the event of a failure by Bayer to deliver the Products
to Purchaser for a prolonged period of time is incapable of accurate estimation
as of the Effective Date.

 

(b)           Subject
to the last sentence of this subsection (b), in the event at the conclusion of
any month Bayer has failed to deliver during the immediately preceding rolling
twelve (12) months an amount of Column Eluate which conforms to the Product
Specifications aggregating at least [***]
of the Orders for the immediately preceding rolling twelve (12) months (“Column Eluate Threshold Deliveries”)
and such failure is not the result of Force Majeure or Purchaser’s failure to
deliver Inputs meeting the Input Specifications to Bayer in accordance with
this Agreement (each, a “Column
Eluate Triggering Event”), then Bayer shall promptly pay
Purchaser liquidated damages as follows:

 

***CONFIDENTIAL TREATMENT REQUESTED

 

20

 

For each month following a Column Eluate Triggering Event Bayer fails
to make Column Eluate Threshold Deliveries, Bayer shall initially pay [***];

 

After Bayer has failed to make Column Eluate Threshold Deliveries for
two consecutive months following a Column Eluate Triggering Event, Bayer shall
thereafter pay [***] per month for
each following consecutive month in which Bayer fails to make Column Eluate
Threshold Deliveries; and

 

After Bayer has failed to make Column Eluate Threshold Deliveries for
five consecutive months following a Column Eluate Triggering Event, Bayer shall
pay [***] for each additional consecutive month in which Bayer
fails to make Column Eluate Threshold Deliveries.

 

The first rolling twelve (12) months shall commence on the first day of
the calendar month immediately following the Effective Date (the “Commencement Date”).
Any liability for payment of damages specifically under this Section 9.4(b)
shall not arise before the first day of the thirteenth month after the
Commencement Date.

 

(c)           In
no event shall the aggregate amount of liquidated damages payable by Bayer for
all such incidences to Purchaser pursuant to subsection (b) above exceed [***] (the “Column Eluate Cap”). From January 1,
2007 through December 31, 2008, the Column Eluate Cap shall be reduced to an
amount equal to [***] minus the
aggregate liquidated damages payable by Bayer pursuant to subsection (b) above
from the Effective Date through December 31, 2006, but not less than zero. No
liquidated damages shall be payable by Bayer pursuant to subsection (b) after
December 31, 2008.

 

(d)           Subject
to the last sentence of this subsection (d), in the event at the conclusion of
any month Bayer has failed to deliver during the immediately preceding rolling
twelve (12) months an amount of ATIII which conforms to the Product
Specifications aggregating at least seventy-five percent (75%) of the Orders
for the immediately preceding rolling twelve (12) months (“ATIII Threshold Deliveries”
and together with the Column Eluate Threshold Deliveries, the “Threshold Deliveries”)
and such failure is not the result of Force Majeure or Purchaser’s failure to
deliver Inputs meeting the Input Specifications to Bayer in accordance with
this Agreement (each, a “ATIII
Triggering Event”), Bayer shall pay Purchaser liquidated damages
as follows:

 

For each month following an ATIII Triggering Event Bayer fails to make
ATIII Threshold Deliveries, Bayer shall initially pay [***];

 

After Bayer has failed to make ATIII Threshold Deliveries for two
consecutive months following an ATIII Triggering Event, Bayer shall thereafter
pay [***] per month for each
following consecutive month in which Bayer fails to make ATIII Threshold
Deliveries; and

 

After Bayer has failed to make ATIII Threshold Deliveries for five
consecutive months following an ATIII Triggering Event, Bayer shall pay [***] per month for each additional
consecutive month in which Bayer fails to make ATIII Threshold Deliveries.

 

***CONFIDENTIAL TREATMENT REQUESTED

 

21

 

The first rolling twelve (12) months shall commence on the Commencement
Date. Any liability for payment of damages specifically under this Section
9.4(d) shall not arise before the first day of the thirteenth month after the
Commencement Date.

 

(e)           In
no event shall the. aggregate amount of liquidated damages payable by Bayer for
all such incidences to Purchaser pursuant to subsection (d) above exceed [***] (the “ATIII Cap”). From January 1, 2007
through December 31, 2008, the ATIII Cap shall be reduced to an amount equal to
[***] minus the aggregate
liquidated damages payable by Bayer pursuant to subsection (d) above from the
Effective Date through December 31, 2006, but not less than zero. No liquidated
damages shall be payable by Bayer pursuant to subsection (d) after December 31,
2008.

 

(f)            If
the liquidated damages provision provided for in this Section 9.4 is deemed
unenforceable for any reason by a court of competent jurisdiction, Bayer shall
pay an amount to Purchaser equal to the direct damages or losses incurred by
Purchaser, including without limitation all lost profits, costs of cover and
delivery penalties but excluding consequential damages as a result of Bayer’s
failure to deliver Products, subject to the Column Eluate Cap and the ATIII
Cap, as applicable.

 

(g)           For
the avoidance of doubt, the requirement to pay liquidated damages in this
Section 9.4 only applies where there has been a failure of Bayer to make
Threshold Deliveries and nothing in this Section 9.4 shall be construed as
relieving Bayer of liability for its failure to deliver Products which conform
to the Product Specifications in the amounts required by Sections 2.1, 2.4 or
2.9 and/or meeting the requirements set forth in Section 2.5 in circumstances
(other than Force Majeure) where Bayer has made Threshold Deliveries, but has
not made full deliveries of the Products in full compliance with an Order
presented in accordance with Section 2.9 (“Circumstance of Under-Delivery”) to the
extent provided in this Section 9.4(g). In the event at the conclusion of any
month Bayer has failed to deliver during the immediately preceding rolling
three (3) months Products which conform to the Product Specifications in an
amount aggregating one hundred percent (100%) of the Orders for the immediately
preceding. rolling three (3) months and Purchaser suffers direct damages as a
result thereof, Purchaser may notify Bayer to that effect, in which case Bayer
shall have three additional months within which to deliver such Products. If
Bayer does in fact deliver such Products within such period, then no damages
shall apply for such Circumstances of Under-Delivery. If Bayer does not deliver
such Products within such period, then Bayer shall be liable to Purchaser for
all direct damages or losses Purchaser suffers, including without limitation
all lost profits, cost of cover and delivery penalties but excluding
consequential damages for each Circumstance of Under-Delivery in an amount not exceeding,
for that calendar year [***]
provided that any such recovery shall be reduced by (i) any amounts previously
paid pursuant to Section 9.4(b) and (d) and (ii) any amount that Purchaser
actually recovers under any insurance it maintains.

 

The first rolling three (3) months shall commence on the date that is
four (4) months following the Commencement Date.

 

***CONFIDENTIAL TREATMENT REQUESTED

22

 

(h)           The
rights and remedies of Purchaser provided in this Section 9.4 shall be
Purchaser’s exclusive remedy for recovery of monetary damages with respect to
Bayer’s failure to deliver Products in amounts required by this Agreement.
Purchaser shall have such non-monetary rights and remedies provided under this Agreement
or under law or in equity for Bayer’s failure to deliver Products in amounts
required by this Agreement, but only limited to the remedy of specific
performance.

 

9.5           Insurance
Recoveries. If and to the extent the indemnifying party has acquired insurance
in compliance with Section 9.3, and to the extent such coverage is inadequate
to cover all Claims asserted against Purchaser and Bayer and if and to the
extent Purchaser or Bayer, as the case may be, has its own policy of insurance
purporting to provide coverage for Claims against Purchaser or Bayer, as the
case may be, Purchaser or Bayer, as the case may be, shall not be entitled to
indemnification from the indemnifying party for such Claims under Section 9.1
until Purchaser or Bayer, as the case may be, has utilized all commercially
reasonable means to recover such loss under its policy of insurance.

 

9.6           Aggregate
Caps. In no event shall Bayer have liability under this Section 9.4 for
non-delivery of Products greater than [***]
in the case of ATM or [***] in the
case of Column Eluate.

 

ARTICLE 10 DISCLAIMER

EACH PARTY MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,
OTHER THAN THOSE EXPRESSLY MADE IN THIS AGREEMENT. ALL OTHER WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ARE HEREBY DISCLAIMED.

 

ARTICLE 11 FORCE MAJEURE

For the purpose of this Agreement, “Force Majeure” shall mean only (i) acts
of God, acts of the public enemy, insurrections, riots, sabotage, strike,
work-stoppage or other labor dispute and natural disasters; (ii) explosions,
fires, flood damage, or loss of electric power not resulting from the
negligence of the Party invoking Force Majeure; (iii) regulatory actions not
attributable to any violation of law after the date hereof on the part of
Purchaser or Bayer, as the case may be, unless, in the case of Purchaser,
Purchaser is required as a result of any statute, law; regulation, ordinance,
rule, judgment, code, order, decree or other requirement of a Regulatory
Authority (“Applicable
Law”), not initiated by Purchaser, to cease or materially
curtail production primarily based upon (x) violation of any Applicable Law
which violation was in existence on the Effective Date or (y) any condition in
existence on the Effective Date or any condition alleged in writing to have
been in existence on or prior to the Effective Date by a Regulatory Authority
which condition remained outstanding on the Effective Date and which condition
constituted a violation or alleged violation of Applicable Law or impacts the
safety or efficacy of the Products; and (iv) in the case of Purchaser, events,
circumstances, conditions and actions outside of the control of Purchaser that
materially and adversely affect the plasma-derived products industry generally,
including interruptions of supply of raw plasma due to viral outbreaks,
eruption of new viruses and similar events, that are reasonably likely to be
subject to 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

23

 

action by any Regulatory Authority; any of (i), (ii), (iii) or (iv) of
which, in the case of the Purchaser, prevents the Purchaser from performing its
obligations under this Agreement, or, any of (i), (ii) or (iii) of which, in
the case of Bayer, prevents Bayer from performing its obligations under this
Agreement; provided that nothing in clause (iii) or (iv) shall excuse Purchaser
from complying with cGMPs or excuse Purchaser from remedying those matters which
were capable of remedy by Purchaser through the application of commercially
reasonable efforts prior to the occurrence of the events identified in (iii) or
(iv) preventing Purchaser from performing under the Agreement. Notwithstanding
anything in this Agreement to the contrary, except Article 7 and Article 12,
the Party experiencing the Force Majeure shall be excused from the performance
of each of its obligations under this Agreement upon a Force Majeure, but only
to the extent performance of any such obligation is necessarily prevented,
hindered or delayed thereby and only during the continuance of any such Force
Majeure, and shall have no liability for damages arising from non-performance
of any obligation excused by a Force Majeure. The Party suffering such Force
Majeure shall invoke this provision by promptly notifying the other Party in
writing of the nature and estimated duration of the suspension period, as well
as the extent to which it will be unable to fulfill its obligations under this
Agreement. Each Party shall be relieved of performance of its obligations under
this Agreement during the time when it is prevented from performing by the
failure of the other Party to perform its obligations or because of any event
of Force Majeure.

 

ARTICLE 12 MISCELLANEOUS

12.1         Consent
to Assignment. This Agreement and all of the provisions hereof shall be
binding upon and inure to the benefit of the Parties hereto and their
respective successors and assigns, and it is not intended to confer upon any
other person any rights or remedies hereunder. Neither this Agreement nor any
of the rights, interests or obligations hereunder may be assigned by any of the
Parties without the prior written consent of the other Party hereto, except
that each Party may at any time assign any or all of its rights or obligations
hereunder to one of its wholly owned subsidiaries (but no such assignment shall
relieve such Party of any of its obligations under this Agreement).
Notwithstanding the foregoing, Purchaser may assign this Agreement and any or
all rights or obligations hereunder to (i) any affiliate of Purchaser provided
that any such affiliate becomes a party to this Agreement, (ii) any lender of
Purchaser as collateral security or (iii) any successor in interest to
Purchaser, provided that any such successor becomes a party to this Agreement;
provided that no assignment under (i), (ii) or (iii) above shall relieve
Purchaser from any obligation hereunder. Bayer may assign this Agreement and
any or all rights or obligations hereunder to (i) any affiliate of Bayer
provided that any such affiliate becomes a party to this Agreement or (ii) any
successor in interest to the Bayer Facility provided that any such successor
becomes a party to this Agreement; provided that no assignment under (i) or
(ii) above shall relieve Bayer from any obligations hereunder. Any purported
assignment in contravention of this Section 12.1 shall be void.

 

12.2         Entire
Agreement and Amendments. This Agreement, together with the Exhibits,
constitutes the entire agreement between the Parties, and merges and supersedes
all previous agreements and understandings between Purchaser and Bayer, whether
oral or written, relating to the subject matter hereof. No amendment,
modification or interpretation of this Agreement will have any effect unless it
is reduced to writing, makes specific reference to this Agreement and is 

 

24

 

signed by all of the Parties. In the event that this Agreement
conflicts with any Order, invoice or other written document, the terms and
conditions of this Agreement shall apply.

 

12.3         Notices.
All notices, requests, demands and other communications required or permitted
hereunder shall be in writing and if mailed by prepaid first class mail or
certified mail, return receipt requested, at any time other than during a
general discontinuance of postal service due to strike, lockout or otherwise,
shall be deemed to have been received on the earlier of the date shown on the
receipt or three (3) business days after the postmarked date thereof and, if
telexed or telecopied, the original notice shall be mailed by prepaid first
class mail within twenty-four (24) hours after sending such notice by telex or
telecopy, and shall be deemed to have been received on the next business day
following dispatch and acknowledgment of receipt by the recipient’s telex or
telecopy machine. In addition, notices hereunder may be delivered by hand, in
which event the notice shall be deemed effective when delivered, or by overnight
courier, in which event the notice shall be deemed to have been received on the
next business day following delivery to such courier. All notices and other
communications under this Agreement shall be given to the parties hereto at the
following addresses:

 

	
  If to Bayer:

  	
   

  
	
   

  	
   

  
	
   

  	
  Bayer HealthCare LLC

  
	
   

  	
  Biological Products Division

  
	
   

  	
  800 Dwight Way

  
	
   

  	
  P.O. Box 1986

  
	
   

  	
  Berkeley, CA 94710

  
	
   

  	
  Attention: Contracts Manager

  
	
   

  	
   

  
	
  With a copy to:

  	
   

  
	
   

  	
   

  
	
   

  	
  Bayer HealthCare LLC

  
	
   

  	
  400 Morgan Lane

  
	
   

  	
  West Haven, CT 06516-4175

  
	
   

  	
  Attention: General Counsel

  
	
   

  	
   

  
	
   

  	
  Marilyn Mooney

  
	
   

  	
  Fulbright & Jaworski L.L.P.

  
	
   

  	
  801 Pennsylvania Avenue, N.W.

  
	
   

  	
  Washington, D.C. 20004

  
	
   

  	
   

  
	
  If to Purchaser:

  	
   

  
	
   

  	
   

  
	
   

  	
  Talecris Biotherapeutics, Inc.

  
	
   

  	
  P.O. Box 13887

  
	
   

  	
  79 TW Alexander Drive

  
	
   

  	
  4101 Research Commons

  
	
   

  	
  Research Triangle Park

  
	
   

  	
  Raleigh, NC 27709

  
	
   

  	
  Fax: (919) 316-6669

  
	
   

  	
   

  

 

25

 

	
  With a copy to:

  	
   

  
	
   

  	
   

  
	
   

  	
  Alison S. Ressler, Esq.

  
	
   

  	
  Sullivan & Cromwell LLP

  
	
   

  	
  1888 Century Park East

  
	
   

  	
  Suite 2100

  
	
   

  	
  Los Angeles, CA 90067

  
	
   

  	
  Fax: (310) 712-8800

  
	
   

  	
   

  
	
   

  	
  Raymond B. Grochowski, Esq.

  
	
   

  	
  Latham & Watkins LLP

  
	
   

  	
  555 11th Street, N.W.

  
	
   

  	
  Suite 1000

  
	
   

  	
  Washington, D.C. 20004

  
	
   

  	
  Fax: (202) 637-2201

  

 

Any Party hereto may change its address specified for notices herein by
designating a new address by notice in accordance with this Section 12.3.

 

12.4         Independent
Contractor. This Agreement does not create an employer-employee.
relationship between the Parties, and is not an agency, joint venture or
partnership. Neither Party shall have the authority to act for the other or to
bind the other in any way, nor to sign the name or to represent that the other
is in any way responsible for the acts or omissions of the other. Bayer shall
maintain its status as an independent contractor engaged in the selling of
Products to Purchaser.

 

12.5         Non-Waiver.
The waiver by either Party of any breach of any term, covenant, condition or
agreement contained herein or any default in the performance of any obligations
hereunder shall not be deemed to be a waiver of any other breach or default of
the same or of any other term, covenant, condition, agreement or obligation.

 

12.6         Choice
of Law. The rights and obligations of the Parties arising out of the
Agreement shall be governed in all respects by the laws of the State of New
York, without giving effect to its conflict of laws provisions.

 

12.7         Captions.
All captions are inserted for convenience only, and will not affect any
construction or interpretation of this Agreement.

 

12.8         Severability.
Any provision of this Agreement which is or may become prohibited or
unenforceable, as a matter of law or regulation, will be ineffective only to
the extent of such prohibition or unenforceability and shall not invalidate the
remaining provisions hereof if the essential purposes of this Agreement may be
given effect despite the prohibition or unenforceability of the affected
provision.

 

12.9         Dispute Resolution.

(a)           Resolution
by the Parties. The Parties shall attempt to resolve any dispute,
controversy, claim or difference arising out of or in connection with, this
Agreement amicably and promptly by 

 

26

 

negotiations between executives who have authority to
settle the controversy. Either Party may give(the other Party written notice of
any dispute not resolved in the normal course of business (“Notice of Dispute”).
Within seven (7) days after delivery of such Notice of Dispute, executives of
the Parties shall agree to meet at a mutually acceptable time and place, and
thereafter, as often as they reasonably deem necessary, to attempt to resolve
the dispute. If the matter has not been resolved within ten (10) days of the
first meeting of such executives (or, if the Parties are unable to mutually
agree upon an acceptable time and place to meet, within ten (10) days of the
disputing Party’s Notice of Dispute), either Party may, by notice to the other
Party (“Dispute
Escalation Notice”), refer the matter to the respective officers
of the Parties designated below.

 

For Bayer:              Executive Vice President, Bayer
HealthCare LLC and President, Biological Product Division

 

With a copy to:

 

Bayer HealthCare LLC

400 Morgan Lane

West Haven, CT 06516-4175

Attention: General Counsel

 

For Purchaser: Chief Executive Officer, Talecris Biotherapeutics, Inc.

 

Such officers shall negotiate in good faith to resolve the matter in an
amicable manner within ten (10) days of the Dispute Escalation Notice. In the
event the matter is not resolved within such ten (10) days, either Party may
initiate arbitration of the dispute as provided for in this Section 12.9.

 

(b)           Binding
Arbitration. In any event, if the dispute, other than with respect to
Section 3.2(ii) or Article 4, is not resolved in accordance with Section
12.9(a) within thirty (30) days of the date in which such dispute arose, either
Party may submit the dispute to binding arbitration by giving the other Party
notice (the “Arbitration
Notice”). Such arbitration shall be conducted in accordance with
the then valid Commercial Arbitration Rules, in effect as of the Effective
Date, of the American Arbitration Association (the “Rules”). The
arbitration shall be held in the English language in New York, New York (U.S.)
in accordance with the substantive law of the State of New York, without giving
effect to its conflict of laws provisions. The arbitration will be conducted by
one (1) arbitrator knowledgeable in the subject matter that is at issue in the
dispute and who is selected by mutual agreement of the Parties or, failing such
agreement by thirty (30) days after the Arbitration Notice was given, will be
selected according to the Rules. Either Party reserves the right to object to
any individual arbitrator who shall be employed by or affiliated with a
competing organization. The arbitrator shall render a decision no later than
ninety (90) days from the date of such arbitrator’s selection. The award of the
arbitrator shall be final and binding on both Parties. Each Party hereby
submits itself to the jurisdiction of the courts of the place where arbitration
is held, but only for the entry of judgment with respect to the decision of the
arbitrator hereunder. Notwithstanding the foregoing, judgment upon the award
may be entered in any court in the state where the arbitration takes place, or
any court having jurisdiction over the Parties. In the event of any actual or
threatened breach or default which could give rise to irreparable harm, nothing
in this Agreement shall prevent either Party from seeking injunctive relief (or
any other provisional remedy or equitable relief) from any court having
jurisdiction over the Parties and the subject matter of this 

 

27

 

dispute to protect their respective rights pending the
outcome of arbitration. The Parties bind themselves to carry out the awards of
the arbitrator. The fees and expenses of the arbitrators, the fees and expenses
of the court report and any expense for a hearing room, and reasonable
attorney’s fees may be awarded to the prevailing party by the arbitrator, or if
such award is not made, will be shared equally by the Parties. The Parties will
otherwise bear their respective expenses of arbitration.

 

(c)           Reviewing
Accountant. If the Parties fail to resolve under Section 12.9(a) any
dispute arising under Section 3.2(ii) within forty-five (45) days, the Parties
shall select a firm of independent certified public accountants of national
standing (the “Reviewing
Accountant”) to resolve the areas of dispute or, if the Parties
fail to agree upon a Reviewing Accountant within twenty (20) days after the
45-day period lapses, such firm shall be selected by lot from among all
so-called “Big Four” firms not having (and not having announced a pending
combination with another firm having) a disqualifying interest with respect to
either Party. The performance of any such firm as the Reviewing Accountant
under this Agreement shall not constitute a disqualifying interest. The Parties
shall make available to the Reviewing Accountant all work papers and all other
information and material in their possession relating to the matters in
dispute. The Reviewing Accountant shall be instructed by the Parties to use its
best efforts to deliver to the Parties its determination as promptly as
practicable after such submission of the dispute to the Reviewing Accountant.
The determination of the Reviewing Accountant shall be final and binding on the
Parties. Each Party shall bear its own expenses and the fees and expenses of
its own representatives and experts, including its independent accountant, in
connection with the preparation, review, dispute (if any) and final resolution
of the dispute. The Parties shall share equally in the costs, expenses and fees
of the Reviewing Accountant.

12.10       Defined
Terms. Defined terms used but not otherwise defined in this Agreement shall
have the meaning ascribed to those terms in the Contribution Agreement.

 

12.11       Set-Off.
No Party to this Agreement shall have any right of set off with respect to
amounts it has an obligation to pay hereunder.

 

(Remainder of this page has been
intentionally left blank)

 

28

 

IN WITNESS WHEREOF, the Parties have caused their duly authorized
representatives to execute this Agreement as of the Effective Date.

 

	
   

  	
  BAYER HEALTHCARE LLC

  
	
   

  	
  Biological Products Division - Berkeley 

  Facility

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Joseph A. Akers

  	
   

  
	
   

  	
  Name:

  	
  Joseph A. Akers

  
	
   

  	
  Title:

  	
  Executive Vice President

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  BAYER HEALTHCARE LLC

  
	
   

  	
  Biological Products Division – Berkeley

  Facility

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Keith R. Abrams

  	
   

  
	
   

  	
  Name:

  	
  Keith R. Abrams

  
	
   

  	
  Title:

  	
  Assistant Secretary

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  TALECRIS BIOTHERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Lawrence D. Stern

  	
   

  
	
   

  	
  Name:

  	
  Lawrence D. Stern

  
	
   

  	
  Title:

  	
  Executive Chairman. President and 

  Chief Executive Officer

  
					

 

 

29

 

 

 

Exhibit Index

 

to

 

Manufacturing Agreement

 

between

 

Bayer HealthCare LLC and Talecris
Biotherapeutics, Inc.

 

	
  Exhibit A

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit B

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit C

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit D

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit E

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit F

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit G

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit H

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit I

  	
  [***]

  
	
   

  	
   

  
	
  Exhibit J

  	
  [***]

  

 

***CONFIDENTIAL TREATMENT REQUESTED

 

Exhibit A

 

[*** 2 pages redacted]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

Exhibit B

 

[*** 11 pages redacted]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit C

 

[***]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit D

 

[*** 5 pages redacted]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit E

 

[*** 3 pages redacted]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit F

 

[*** 3 pages redacted]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit G

 

[*** 3 pages redacted]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit H

 

[***]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit I

 

[***]

 

 

***CONFIDENTIAL TREATMENT REQUESTED

 

 

 

Exhibit J

 

[***]

 

 

***CONFIDENTIAL TREATMENT REQUESTEDExhibit 10.33.1

 

Execution Copy

 

AMENDED AND RESTATED

MASTER SERVICES AGREEMENT

BETWEEN

BAYER HEALTHCARE LLC AND TALECRIS
BIOTHERAPEUTICS INC.

 

This Amended
and Restated Master Services Agreement (this “Agreement”) is made and entered
into as of April 1, 2006 by and between Bayer HealthCare LLC (“Bayer”)
and Talecris Biotherapeutics, Inc. (“Talecris”). Capitalized terms used and not
otherwise defined herein shall have the meanings ascribed to such terms in the
Original Agreement (as defined below). Bayer and Talecris are sometimes
referred to herein collectively as the “Parties,” and individually as a “Party.”

 

WITNESSETH:

 

WHEREAS,
the Parties entered into that certain Master Services Agreement as of March 31,
2005 (the “Original Agreement”); and

 

WHEREAS,
the Parties wish to amend and restate the Original Agreement effective as of
April 1, 2006 (the “Effective Date”), to extend the provision of certain
services by Bayer and its affiliates to Talecris on the terms and subject to
the conditions set forth herein;

 

NOW,
THEREFORE, in consideration of the mutual covenants
and agreements contained herein, the Parties agree, intending to be legally
bound, as follows effective as of the Effective Date:

 

ARTICLE I

SERVICES TO BE PROVIDED

 

1.1                                 Services
to be Provided.

 

(a)                                  Bayer
HealthCare LLC. Bayer HealthCare LLC shall, or shall cause its Affiliates
to, provide to Talecris the services identified in Exhibit A hereto.

 

(b)                                 Bayer
Corporate and Business Services LLC. Bayer shall cause Bayer Corporate and
Business Services LLC or its Affiliates to provide to Talecris the services
identified in Exhibit B hereto.

 

(c)                                  Bayer
Pharmaceuticals Corporation. Bayer shall cause Bayer Pharmaceuticals
Corporation or its Affiliates to provide to Talecris, the services identified
in Exhibit C hereto.

 

(d)                                 Bayer
Vital. Bayer shall cause Bayer Vital or its Affiliates to provide to
Talecris the services identified in Exhibit D hereto.

 

(e)                                  Bayer
AG. Bayer shall cause Bayer AG or its Affiliates to provide to Talecris the
services identified in Exhibit E hereto.

 

 

All of the
services set forth on the attached Exhibits A, B, C, D and E, as such
Exhibits may be amended from time to time pursuant to this Agreement, are
collectively hereinafter referred to as the “Services”. Only the
services described in those exhibits are being provided. Upon signing, this
Agreement supersedes in its entirety any obligation of Bayer or its Affiliates
or any rights of Talecris to request or demand any Services or Additional
Services provided for in Section 3.9 of the Original Agreement or elsewhere in
the Original Agreement after March 31, 2006.

 

Notwithstanding
the foregoing, neither Bayer nor its Affiliates shall have any obligation to
perform any Services enumerated in Exhibits A-2, A-3, C and D-1 if the performance
of any such Service would be unlawful or have the appearance of illegality or
would involve a conflict of interest or, in the case of Services that would be
inconsistent with Bayer or its Affiliates’ corporate practices, in the event
the parties have been unable to reach mutual agreement on a resolution of any
such inconsistencies.

 

1.2                                 Compensation
for Services. The amount that Talecris is obligated to Bayer and its
Affiliates for the Services is set forth on Exhibits A, B, C, D, and E. Except
as provided otherwise on Exhibits A, B, C, D, and E, all fees payable for
Services are fixed and inclusive of overhead, including without limitation
general and administrative costs, costs of facilities, information technology
and payroll costs as necessary to support the Services, Taxes and employee
costs (including compensation, benefits, travel and other related costs).

 

1.3                                 Audit.
Talecris shall have the right at its expense, directly or through
representatives, upon reasonable notice and during business hours, to audit
Bayer’s and its Affiliates books and records related to and reasonably
necessary to evaluate, with respect to those Services enumerated in Exhibit
A-3, (i) the invoiced volume of such services, the payment of which is based on
volume, and (ii) any out-of-pocket costs incurred in providing those Services
for which fees payable to Bayer are based on Bayer’s Direct Costs, provided
that (x) Talecris may only exercise this audit right only once during the Term
of this Agreement, (y) Talecris shall provide Bayer advance written notice of
its intent to conduct the audit and (z) Talecris and Bayer shall (and Bayer
shall cause any Affiliate to) cooperate as reasonably needed in order to
complete any such audit as promptly as reasonably possible under the
circumstances.

 

ARTICLE II

MISCELLANEOUS PROVISIONS

 

2.1                                 Standard
of Performance. Each Service shall be provided in a timely, professional
and workmanlike manner and provided with a level of quality, degree of care,
and skill, diligence and timeliness that is not materially different than that
with which such service had been performed for the normal ongoing operations of
the Plasma Business during the twelve (12) month period immediately preceding
Closing.

 

2.2                                 Operational
Reporting. With respect to each Service, Bayer shall continue to provide to
Talecris copies of the reports, statements, activity summaries, or other forms,
Bayer or its Affiliates were providing to Talecris prior to the Effective Date
related to providing such Service (the “Service Reports”).

 

2

 

2.3                                 Cooperation.

 

(a)                                  Talecris
shall make available on a timely basis to Bayer and to its employees,
representatives, Affiliates and Contractors (collectively, “Representatives”),
the information reasonably requested by Bayer to enable Bayer and its
Representatives to provide the Services. Talecris hereby represents and
warrants that all such information shall be true, complete and accurate in all
respects and will not contain any untrue information or fail to include any
information that would make such information false or misleading. Bayer and its
Representatives shall be entitled to rely on such information without further
inquiry. Talecris shall give Bayer and its Representatives reasonable access,
during normal business hours and at such other times as are reasonably required
and subject to such reasonable restrictions as Talecris may from time to time
prescribe, to Talecris’ premises solely to the extent reasonably necessary to
enable Bayer and its Representatives to provide the Services.

 

(b)                                 Except
with respect to those Services enumerated in Service Levels C-1 and C-2, Bayer
shall provide, and shall cause its Affiliates to provide, as appropriate,
Talecris and its Representatives reasonable access following the end of the
Term, during normal business hours and at such other times as are reasonably
required and subject to such reasonable restrictions as Bayer may from time to
time prescribe, to Bayer’s Representatives, books, records, offices, and
properties directly related to Bayer’s support of the Plasma Business and
reasonably required to permit Talecris or any contractor selected by Talecris
to develop and provide its own stand- alone services to replace the Services;
provided that Talecris shall reimburse Bayer for its Direct Costs plus 30% in
providing such access, except to the extent that Talecris is entitled to such
access without further payment under Sections 7.3 and 8.4(d) of the Joint
Contribution Agreement, in which case the relevant sections of the Joint
Contribution Agreement shall control.

 

(c)                                  For
training of Talecris employees in preparation for assumption of Services in
Exhibit C, Bayer and Talecris agree to work together with an objective of
limiting training hours in total to 150 hours for all Bayer Pharmaceuticals (“BP”)
employees and no more than 15% of any one employee’s time in any given month.
The training schedule shall be mutually agreed to by Bayer and Talecris to
allow for scheduling of resources and facilities. The training time will be
calculated as to each BP employee involved in training - i.e. if there are 2 BP
employees present, each hour of training will be counted as two hours (2
employees times 1 hour each). The training will take place at Bayer’s West Haven
facility and will include providing space for Talecris personnel adjacent to
the workspace for BP personnel performing the training.

 

(d)                                 “Direct
Costs” is defined herein to mean Bayer’s reasonable direct costs, which
includes all (i) employee costs (including, for example, salaries, benefits,
relocation, travel, and training and development) and employee supporting costs
(including, for example, computer and software, telephone usage, supplies, and 

 

3

 

 

depreciation of office equipment and furnishings) for
employees working directly on such service, pro rated for the amount of time
spent by such employees working directly on such service, but in no event shall
this include any general overhead costs (including, for example, depreciation
for office building space, information technology infrastructure, site
maintenance, medical department, cafeteria, security, communications, safety,
heating and cooling, water and sewage, electricity, gas, and general administration),
and (ii) documented out-of-pocket costs incurred in the provision of such
service.

 

2.4                                 Payment
Terms. Each month, Bayer or the appropriate Affiliate providing the Service
shall submit to Talecris an invoice setting forth the monthly fees for the
Services provided during the preceding calendar month. The foregoing shall not
limit Bayer’s or its Affiliate’s right to submit corrective invoices in the
event there are unbilled amounts owing for Services, or amounts to which Bayer
or its Affiliates is entitled to compensation or reimbursement hereunder which
were not previously invoiced. Payment of all amounts owed by Talecris shall be
remitted on or before thirty (30) days from the date the invoice therefore is
submitted to Talecris provided, however, that if Talecris in good faith
disputes the validity or amount of any charge on such invoice, other than for
Services which are provided on a fixed-fee basis, then Talecris shall (A)
promptly provide Bayer with written notice of such disputed item, which notice
shall specifically identify the disputed item and explain the reason for such
dispute, and (B) remit when due any undisputed amount. In the event of any such
dispute, Talecris’ and Bayer’s Contract Managers shall promptly discuss and
attempt to resolve any differences in good faith, To the extent that agreement
is reached within thirty (30) days of such dispute arising, Talecris shall
promptly pay (or Bayer shall promptly refund) such amount, if any, as shall be
so agreed, together with interest accruing thereon since the date such payment
was due or made, as applicable, at the London Inter-Bank Offered Rate. To the
extent no such agreement is reached within such thirty (30) day period, the
dispute shall be resolved in accordance with Section 2.19(c) and (d) hereof. No
such dispute shall affect the obligation of Bayer to continue to provide or
cause to be provided the Services in accordance with this Agreement, provided
that Talecris exercises good faith efforts to resolve such dispute on a timely
basis. Late payments shall accrue interest at the rate of 1.0% per month, pro
rated daily. All invoices shall be issued and paid in U.S. dollars. For
purposes of determining the U.S. dollar invoice amount for the services of
Bayer Vital and Bayer AG, the monthly payment obligations set forth in Euros on
Exhibits D and E shall be converted to U.S. dollars based on the exchange rate
published in the Wall Street Journal on the last
business day of the month for which such invoice is issued, which exchange rate
shall be determinate except in the case of manifest error.

 

2.5                                 Compliance
with Laws Licenses and Permits; Consents. Bayer and its Affiliates shall
perform all Services in compliance with all applicable statutes, Laws,
regulations, ordinances, rules, judgments, codes, orders, decrees, permits,
approvals, concessions, grants, franchises, licenses, guidance’s, agreements or
requirements of any Governmental Authority having jurisdiction over the matter
or matters in question and will, at its expense, maintain all permits and
licenses, and obtain all consents, reasonably necessary for the provision of
the Services.

 

4

 

2.6                                 Confidentiality.

 

(a)                                  Confidentiality
Obligations. All information provided by one Party to the other Party in
connection with this Agreement shall be maintained in strict confidence by the
receiving Party. Such information shall remain the property of the providing
Party, and the receiving Party shall not make use of any such information
except for the purposes for which it was provided. At the termination of this
Agreement, upon request, the receiving Party shall promptly return to the
providing Party or destroy any physical embodiments (including copies) of any
such information. Each Party agrees to keep confidential the existence of this
Agreement, as well as all of its terms and conditions; provided that if a
public announcement or disclosure is required by law, rule, regulation, court
order, subpoena, interrogatory or other discovery request (including without
limitation applicable securities laws or stock exchange regulations), and
subject to Section 2.6(b)(v), the Party required to make the public
announcement or disclosure shall be permitted to make such disclosure and shall
provide prompt prior written notice of such requirement to the other Party, and
the Parties shall thereafter negotiate in good faith, to the extent appropriate
and feasible, the contents of the public announcement or disclosure.

 

(b)                                 Exceptions.
The covenants of the receiving Party contained in Section 2.6(a) shall not
apply to information which: (i) is already in the public domain at the time of
disclosure; (ii) becomes part of the public domain through no action or
omission of the receiving Party after disclosure to the receiving Party; (iii)
is already known to the receiving Party on a non-confidential basis at the time
of disclosure, as evidenced by the receiving Party’s written records, except
for information that was known to Bayer or its Affiliates prior to the date hereof;
(iv) has been or is disclosed to the receiving Party in good faith by a third
party who was or is not, at the time of disclosure, under any obligation of
confidence to the other Party hereto at the time the third party disclosed such
information, except for proprietary information concerning the Plasma Business
disclosed to Bayer or its Affiliates; or (v) is required to be disclosed by
law, provided that the receiving Party shall cooperate with the disclosing
Party (at the disclosing Party’s expense) in obtaining any available protection
for such information to be disclosed.

 

(c)                                  Plasma
Business Information. Talecris shall be deemed the providing Party and
Bayer and its Representatives shall be receiving Parties for purposes of the
rights and obligations set forth in Sections 2.6(a) and (b) as to Plasma
Business information supplied by Talecris to Bayer.

 

(d)                                 Term
of Obligations.  This Section 2.6
shall survive termination of this Agreement for a period of five (5) years.

 

(e)                                  Applicability
to Contractors. In the event either Party uses a Contractor, such Party
will cause such Contractor to acknowledge in writing that such Contractor
agrees to abide by the terms of this Section 2.6.

 

 

 

5

 

2.7                                 Primary
Points of Contact.

 

(a)                                  Appointment
and Responsibilities. Each Party shall appoint an individual to act as the
primary point of operational contact for the administration and operation of
this Agreement, as follows:

 

(i)                                     The
individual appointed by Talecris as the primary point of operational contact
pursuant to this Section 2.7(a)(i) shall initially be Jim Moose (the “Talecris
Contract Manager”). The Talecris Contract Manager will have overall
responsibility for: (a) coordinating, on behalf of Talecris, all activities
undertaken by Talecris hereunder and the performance of the Talecris
obligations hereunder, (b) coordinating the performance of the Services with
Bayer and its Affiliates, (c) acting as a day-to-day contact with the Bayer
Contract Manager (as defined below), and (d) making available to Bayer the
data, facilities, resources, and other support services from Talecris required
for Bayer and its Affiliates to be able to perform the Services in accordance
with the terms of this Agreement. Talecris may replace the Talecris Contract
Manager from time to time upon written notice to Bayer. Talecris shall use
commercially reasonable efforts to provide at least thirty (30) days prior
written notice of any such change.

 

(ii)                                  The
individual appointed by Bayer as the primary point of operational contact
pursuant to this Section 2.8(a)(ii) shall initially be Johannes Frick (the “Bayer
Contract Manager”). The Bayer Contract Manager will have overall
responsibility for: (a) coordinating, on behalf of Bayer, all activities
undertaken by Bayer and its Affiliates hereunder and the performance of the
Bayer obligations hereunder, (b) coordinating the performance of the Services
with Talecris, (c) acting as a day-to-day contact with the Talecris Contract
Manager, and (d) providing Talecris with service performance information and
communicating with the Talecris Contract Manager regarding Service requirements
and Service management. Bayer may replace the Bayer Contract Manager from time
to time upon written notice to Talecris. Bayer shall use commercially reasonable
efforts to provide at least thirty (30) days prior written notice of any such
change.

 

(b)                                 Review
Meetings. The Bayer Contract Manager and the Talecris Contract Manager
(together, the “Contract Managers”) will meet periodically to review
Bayer’s performance of the Services under this Agreement, to discuss any
problems that are unresolved and any details concerning their expected
resolution, and to discuss the wind down and termination of the various
Services.

 

(c)                                  In
the event that the Mutual Recognition Procedure (the “MRP”) for the
expansion of the Gamunex and Prolastin registrations in the EU, and the
transfer of the associated marketing authorizations (the “Authorizations
Transfer”) to Talecris or it designee have, for any reason, not been
completed as of the expiration of the Term despite Talecris’s commercially
reasonable efforts to 

 

 

6

 

complete the MRP and the Authorizations Transfer, then
any Service then being provided by Bayer Vital, Bayer AG or their respective
Affiliates and reasonably required by Talecris for completing the MRP and the
Authorizations Transfer shall be extended for an additional period of three (3)
months, with further monthly extensions as mutually (and reasonably) agreed
upon by the Parties, until such time as the MRP and the Authorizations Transfer
are completed. Such extended Services shall be provided on such terms as they
were provided during the Term, subject to adjustment in accordance with
subsection (e) of this Section 2.7.

 

(d)                                 In
the event that the clinical studies services provided to Talecris by Bayer
Vital, Bayer AG or their respective Affiliates as part of the Service during
the Term are reasonably required by Talecris after the expiration of the Term,
then such shall be extended for an additional period of one (1) year, with
further annual extensions as mutually (and reasonably) agreed upon by the
Parties but in no event for an aggregate period beyond March 31, 2009. Such
extended Services or shall be provided on such terms as they were provided
during the Term, subject to pro ration for any changes in the volume of such
services rendered during the extensions and further subject to adjustment in
accordance with subsection (e) of this Section 2.7.

 

(e)                                  [***]

 

2.8                                 Term.
Except as provided in the last sentence of this Section, this Agreement shall
end March 31, 2007; provided, however, that Talecris may earlier terminate any
of the levels of Service designated in the subnumbers to Exhibits A-E (the “Service
Levels”) upon at least three months’ (six months in the case of those Services
in Service Levels A-3 and D-1) prior written notice. For the avoidance of
doubt, certain Services included on Exhibit C to this Agreement shall terminate
as of the date set forth on those exhibits for such Services.

 

2.9                                 Termination;
Damage Limitations and Indemnity.

 

(a)                                  Damage
Limitations.

 

(i)                                     If
Bayer or any of its Affiliates commits a substantial breach or violation of any
material provision of this Agreement, and such breach or violation is not cured
within sixty days after receiving written notice thereof from Talecris,
Talecris will be entitled to recover from the breaching party all direct Losses
arising from such breach or violation, but not including lost 

 

*** CONFIDENTIAL TREATMENT REQUESTED

 

 

7

 

                                                profits
or consequential damages, and provided that any such recovery shall be reduced
by the amount Talecris recovers with respect to such Losses under any insurance
it maintains and the maximum amount that Talecris may recover is the amount
that Talecris would have otherwise paid for such Service under this Agreement
from the time of such breach or violation until the end of the Term.

 

(ii)                                  If
Talecris or any of its Affiliates commits a substantial breach or violation of
any material provision of this Agreement (other than default in payment under
Section 2.4), and such breach or violation is not cured within sixty days after
receiving written notice thereof from Bayer, Bayer will be entitled to recover
from the breaching party all direct Losses arising from such breach or
violation, but not including lost profits or consequential damages, and
provided that any such recovery shall be reduced by the amount Bayer recovers
with respect to such Losses under any insurance it maintains and the maximum
amount that Bayer may recover is the amount that Bayer would have otherwise
been paid for such Service under this Agreement from the time of such breach or
violation until the end of the Term.

 

(b)                                 Bayer
Right to Terminate. If Talecris commits a substantial breach or violation
of its obligation to pay for the Services, and such breach or violation is not
cured within sixty days after receiving written notice thereof from Bayer,
Bayer may terminate this Agreement and will be entitled to recover from
Talecris its direct Losses, including an amount equal to the most recent month’s
fees for Services under this Agreement multiplied by three (multiplied by six
in the case of those Services in Service Levels A-3 and D-1).

 

(c)                                  Other
Remedies. In addition to, and not in limitation of, the rights and remedies
set forth in this Section 2.10, each Party shall have such non-monetary rights
and remedies provided under this Agreement or under law or in equity for
breaches of the Agreement, but only limited to the remedy of specific
performance.

 

(d)                                 Exception.
It is understood and agreed that a good faith dispute concerning billing or
invoice matters under Section 2.4 shall not constitute a breach, violation or
termination of this Agreement for purposes of this Section 2.10.

 

(e)                                  Indemnities.

 

(i)                                     Talecris
hereby agrees to indemnify, save, defend and hold harmless Bayer and its
Affiliates and its and their respective directors, officers, managers,
employees, representatives, consultants, stockholders, controlling persons,
attorneys and agents and each of their respective heirs, executors, successors
and assigns (together the “Bayer Group”) harmless from and against any and all
claims, suits, actions, liabilities, expenses and/or Losses, including punitive
or exemplary damages and attorneys’ fees and expenses (“Claims”; each, a “Claim”)
asserted by a 

 

 

8

 

 

                                                person
or entity other than a member of the Bayer Group arising from or attributable
to, directly or indirectly to any act or omission of Talecris or any Service
provided by the Bayer Group hereunder, except where such Claim arises out of a
material breach by Bayer or its Affiliates of Bayer’s obligations under this
Agreement.

 

(ii)           Bayer
hereby agrees to indemnify, save, defend and hold harmless Talecris and its
Affiliates and its and their respective directors, officers, managers,
employees, representatives, consultants, stockholders, controlling persons,
attorneys and agents and each of their respective heirs, executors, successors
and assigns (together the “Talecris and Affiliates”) harmless from and against
any and all Claims, asserted by a person or entity other than Talecris and Affiliates
to the extent arising from or attributable to, directly or indirectly a
material breach by Bayer or its Affiliates of Bayer’s obligations under this
Agreement.

 

(iii)          Notwithstanding
anything to the contrary in this Agreement, nothing herein shall be deemed to
alter the rights of any party under Sections 8.2 or 8.3 of the Amended and
Restated Joint Contribution Agreement by and between Bayer HealthCare LLC and
Talecris Holdings LLC, Talecris BioTherapeutics Holdings Corp., and Talecris
BioTherapeutics, Inc. of March 30, 2005 (“Restated Joint Contribution Agreement”).

 

(f)            Special
Indemnity. Talecris represents and
warrants that all information provided to Bayer and its Affiliates in
connection with the Services shall be true, complete and accurate and will not
include any untrue information or fail to include any information that would
make such information false or misleading. Bayer and its
Affiliates shall be entitled to rely on such information without further
inquiry. Talecris hereby agrees to indemnify,
save, defend and hold harmless the Bayer Group from and against any and all
Claims asserted by a person or entity other than a member of the Bayer Group
arising from or attributable to, directly or indirectly any claims arising out
of the treatment given any transaction as directed by Talecris and serviced by
Bayer or its Affiliates pursuant to this Agreement that is different from the
treatment Bayer and its Affiliates had followed in connection with the same or
similar transaction.

 

2.10         Inconsistency. To the extent the terms of the Restated Joint Contribution
Agreement are inconsistent with the terms of this Agreement, the terms of this
Agreement shall control. If the
Restated Joint Contribution Agreement contains terms applicable to the Parties’
rights and obligations under this Agreement, and this Agreement does not
address such terms, the terms set forth in the Joint Contribution Agreement
shall control.

 

2.11         Expenses
Related to Negotiation of Extension. Each Party
shall be responsible for all fees, costs and expenses incurred by it in
connection with the negotiation and execution of this Agreement.

 

 

9

2.12         Relationship
of Parties. In providing the Services, each
Person doing so is acting as and shall be considered an independent contractor. Nothing herein contained shall be deemed or construed by
Bayer, Talecris or any other Person as creating the relationship of principal
and agent, partnership, joint employers or joint venture between the Parties. All employees and representatives of Bayer or its
Affiliates or Contractors, as applicable, shall be deemed for all purposes
(including compensation and employee benefits) to be employees or
representatives solely of Bayer or its Affiliates or Contractors, as
applicable, and not to be employees or representatives of Talecris. In
performing their respective duties hereunder, all such employees and
representatives of Bayer or its Affiliates or Contractors, as applicable, shall
be under the direction, control and supervision of Bayer or its Affiliates or
Contractors, as applicable (and not of Talecris), and Bayer or its Affiliates
or Contractors, as applicable, shall have the sole right to exercise all
authority with respect to the employment (including termination of employment),
assignment and compensation of such employees and representatives. Bayer is not
authorized to, and none of Bayer’s or its Affiliates’ or Contractors’ employees
or representatives shall at any time attempt to, (i) act on behalf of Talecris
other than as authorized by Talecris, or (ii) bind Talecris in any manner
whatsoever to any obligations. None of Bayer, its Affiliates or Contractors or
their respective employees or representatives shall engage in any acts that may
lead any person to believe that such party is an officer, employee or
representative of Talecris.

 

2.13                           Entire
Agreement; Amendment; Waiver. This
Agreement (including Exhibits hereto) constitutes the entire understanding
between the Parties with respect to the subject matter hereof and supersedes
all prior agreements and understandings relating to such subject matter,
including the Original Agreement and any and all service level agreements, as
of the Effective Date. No provision
of this Agreement shall be deemed waived, amended, supplemented or modified by
any Party, unless such waiver, amendment, supplement or modification is in
writing and signed by the authorized representative of the Party against whom
it is sought to enforce such waiver, amendment, supplement or modification. No delay of or omission in the exercise of any right,
power or remedy accruing to either Party as a result of any breach or default
by the other Party under this Agreement shall impair any such right, power or
remedy, nor shall it be construed as a waiver of or acquiescence in any such
breach or default, or of any similar breach or default occurring later; nor
shall any waiver of any single breach or default be deemed a waiver of any
other breach or default occurring before or after that waiver.

 

2.14                           Headings. The article, section and paragraph headings contained in
this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.

 

2.15                           Counterparts. This Agreement may be executed in counterparts which,
taken together, shall constitute the whole agreement. Executed
signatures to this Agreement may be delivered by any standard electronic means
and any such electronically delivered signatures shall be construed as manually
executed signatures.

 

2.16                           Severability. In the event that any provision or requirement of this
Agreement is in violation of any law or regulation or otherwise found to be
invalid or unenforceable in 

 

10

 

any jurisdiction, (a) such provision or requirement
shall not be enforced except to the extent it is not in violation of such laws
or regulations or otherwise invalid or unenforceable, (b) the Parties will
promptly renegotiate to restore such provision or requirement of this Agreement
as near as possible to its original interest and effect, and (c) all other
provisions and requirements of this Agreement shall remain in full force and
effect.

 

2.17                           Setoff. No Party shall have any right of set-off with respect to
amounts it has an obligation to pay hereunder.

 

2.18                           Notices. All notices and other communications hereunder shall be in
writing (including facsimile or similar writing) and shall be sent, delivered
or mailed, addressed or faxed:

 

	
  (a)

  	
  if to Talecris, to:

  	
  Talecris BioTherapeutics, Inc.

  Attn.: General Counsel

  P.O. Box 110526

  79 TW Alexander Drive

  4101 Research Commons Research

  Triangle Park

  Raleigh, NC 27709

  Fax: (919) 316-6677

  
	
   

  	
   

  	
   

  
	
  (b)

  	
  if to Bayer, to:

  	
  Paul R. Berry

  General Counsel and Secretary

  Bayer HealthCare LLC

  400 Morgan Lane

  West Haven, CT 06516-4175

  Fax: (203)812-2795

  

  with a copy (which shall not constitute notice) to:

  

  Johannes Frick

  VP Business Planning & Administration

  Bayer HealthCare LLC

  800 Dwight Way

  Berkeley, CA 94710

  

  Marilyn Mooney, Esq.

  Fulbright & Jaworski L.L.P.

  801 Pennsylvania Avenue, N.W.

  Washington, D.C. 20004

  Fax: (202) 662-4643

  

 

Each such
notice or other communication shall be given (i) by hand delivery, (ii) by
nationally recognized courier service, or (iii) by facsimile, receipt confirmed. Each such notice or communication shall be effective (x)
if delivered by hand or by nationally recognized courier service, when
delivered at the address specified in this Section 2.18 (or in accordance with
the 

 

 

11

 

latest
unrevoked direction from such Party), and (y) if given by facsimile, when such
facsimile is transmitted to the facsimile number specified in this Section 2.18
(or in accordance with the latest unrevoked direction from such Party), and
confirmation is received; provided that, the transmission of all pages
is complete prior to 5:00 p.m. Eastern Standard Time, on a Business Day (as
defined in the Joint Contribution Agreement), and if complete after such time
or on a non-Business Day, then such transmission shall be effective as of the
next succeeding Business Day.

 

2.19                           Dispute
Resolution.

 

(a)                                  The
Parties shall attempt in good faith to resolve any controversy or claim arising
out or relating to this Agreement promptly by negotiations between representatives
and managers of the Parties who have authority to settle the controversy.

 

(b)                                 If
a controversy or claim should arise, the Contract Managers will meet at least
once within ten (10) days of the date the controversy arose and will attempt to
resolve the matter. The Contract Managers will make
every good faith effort to meet as soon as reasonably possible at a mutually
agreed time and place.

 

(c)                                  If
the dispute is not resolved by the Contract Managers within thirty (30) days of
their first meeting, or if the Talecris Contract Manager and the Bayer Contract
Manager earlier agree that the dispute will not be resolved by them, the
Contract Managers shall refer the matter to senior executives within their
respective organizations. Thereupon,
the Contract Managers shall promptly prepare and exchange memoranda stating (i)
the issues in dispute and their respective position, summarizing the evidence
and arguments supporting their positions, and the negotiations which have taken
place, and attaching relevant documents, and (ii) the name and title of the
senior executive who will represent that Party. The
senior executives shall meet for negotiations (which may be held
telephonically) at a mutually agreed time and place within fourteen (14) days
of the end of the thirty day period referred to above and thereafter as often
as they deem reasonably necessary to exchange relevant information and to
attempt to resolve the dispute.

 

(d)                                 If
the matter has not been resolved within thirty (30) days of the meeting of the
senior executives, or if either Party will not meet within thirty (30) days of
the end of the thirty day period referred to in the preceding paragraph, the
dispute shall be referred to and finally resolved by arbitration conducted in
accordance with the rules set forth in Sections 11.7(b) through 11.7(m) of the
Restated Joint Contribution Agreement. The decision
and award of the arbitral tribunal shall be made by majority decision and shall
be final, nonappealable and binding on both Parties and their successors and
assigns.

 

2.20                           Governing
Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York applicable
to contracts made and to be performed therein, without giving effect to the
principles of conflicts of law thereof.

 

12

 

2.21                           Jurisdiction
and Venue. Any action or proceeding with
respect to this Agreement or for recognition and enforcement of any judgment or
arbitration award in respect thereof brought by any Party or its successors or
assigns, shall be brought and determined in a New York state court or U.S. federal district court in New York, and each of the
Parties hereby irrevocably submits with regard to any such action or proceeding
for itself, generally and unconditionally, to the exclusive jurisdiction of the
aforesaid courts; provided, however, that such consent to jurisdiction is
solely for the purpose referred to in this Section 2.21 and shall not be deemed
to be general submission to the jurisdiction of said courts or in the State of
New York other than for such purpose.

 

2.22                           Assignment. This Agreement and all of the provisions hereof shall be
binding upon and inure to the benefit of the Parties hereto and their
respective successors and assigns, and it is not intended to confer upon any
other person any rights or remedies hereunder. Neither
this Agreement nor any of the rights, interests or obligations hereunder may be
assigned by any of the Parties without the prior written consent of the other Party
hereto, except that each Party may at any time assign any or all of its rights
or obligations hereunder to one of its wholly owned subsidiaries (but no such
assignment shall relieve such Party of any of its obligations under this
Agreement). Notwithstanding the foregoing,
Talecris may assign this Agreement and any or all rights or obligations
hereunder to (i) any affiliate of Talecris provided that any such affiliate
becomes a party to this Agreement, (ii) any lender of Talecris as collateral
security or (iii) any successor in interest to Talecris, provided that any such
successor becomes a party to this Agreement; provided that no assignment under
(i), (ii) or (iii) above shall relieve Talecris from any obligation hereunder
and, in the case of (i) and (iii) above, such assignee has qualifications and
capabilities needed to perform Talecris’s obligations hereunder. Bayer may assign this Agreement and any or all rights or
obligations hereunder to (i) any affiliate of Bayer provided that any such
affiliate becomes a party to this Agreement or (ii) any successor in interest
to Bayer provided that any such successor becomes a party to this Agreement;
provided that no assignment under (i) or (ii) above shall relieve Bayer from
any obligation hereunder, and in the case of (i) and (ii), such assignee has
qualifications and capabilities needed to perform Bayer’s or its Affiliates’
obligations hereunder. Any purported
assignment in contravention of this Section 2.22 shall be void.

 

2.23                           Force
Majeure. For the purpose of this Agreement, “Force Majeure” shall mean only (i)
acts of God, acts of the public enemy, insurrections, riots, sabotage, strike,
work stoppage or other labor dispute and natural disasters and (ii) explosions,
fires, flood damage, or loss of electric power not resulting from the
negligence of the Party invoking Force Majeure, either of (i) or (ii) which
prevents a Party from performing its obligations under this Agreement. Notwithstanding anything in this Agreement to the
contrary, except Section 2.7, the Party experiencing the Force Majeure shall be
excused from the performance of each of its obligations under this Agreement
upon a Force Majeure, but only to the extent performance of any such obligation
is necessarily prevented, hindered or delayed thereby and only during the
continuance of any such Force Majeure, and shall have no liability for damages
arising from non-performance of any obligation excused by a Force Majeure. The Party suffering such Force Majeure shall invoke this
provision by promptly notifying the other Party in writing of the nature and
estimated duration of the suspension period, as well as the extent to which it
will be unable to fulfill its obligations

 

13

 

 

under the Agreement. Each Party
shall be relieved of performance of its obligations under this Agreement during
the time when it is prevented from performing by the failure of the other Party
to perform its obligations or because of any event of Force Majeure.

 

(a)                                  In
the event that Bayer or any of its Affiliates providing any Service suffers a
Force Majeure with respect to such Service, and any facilities, personnel, or
other resources that are existing resources used by Bayer or such Affiliate in
performing activities and functions on behalf of itself or other parties that
are included in or similar to such Service, Bayer or such Affiliate shall use
such commercially reasonable efforts to use such facilities, personnel, and
resources in continuing to provide such Service on a pro rata basis with other
uses of such facilities, personnel, and resources, and a failure to comply with
this requirement shall not be excused by such Force Majeure. For
the avoidance of doubt, (i) this provision shall not require Bayer and its
Affiliates to provide such Service where it has previously been performed by an
independent Contractor but shall require Bayer and its Affiliates to use such
reasonable efforts to cause such independent Contractors also performing
similar Services for Bayer and its Affiliates to comply with this subsection
(b), and (ii) in such circumstances, in no event shall Bayer or any of its
Affiliates be required to acquire additional assets, equipment, rights or
properties other than in its ordinary course of business.

 

2.24                           Non
Solicitation. With respect to those employees
of Bayer or its Affiliates engaged in the performance of services, the
provisions of Section 11.5(e) of the Joint Contribution Agreement shall apply
until the termination of the provision of such services.

 

2.25                           Transfer
of Records. Bayer may continue to retain
only those Plasma Business records of Talecris as are necessary in order for
Bayer to perform the Services. At the
conclusion of the term of this Agreement, Bayer will transfer such Plasma
Business records that are necessary in order for Bayer to provide the Services
to Talecris in hard copy or, if available, electronic format. For the avoidance of doubt, the business records of Bayer
regarding the performance of the Services hereunder shall remain with Bayer;
provided that on reasonable advance notice and subject to reasonable
restrictions as Bayer may prescribe, in the event of a reasonable business need
therefore, Bayer will provide Talecris with reasonable access to such records,
provided that (i) such records are readily and reasonably available and (ii)
that Talecris shall reimburse Bayer for its costs in providing such access.

 

14

 

IN WITNESS
WHEREOF, the Parties have caused this Agreement to be signed by their
respective officers thereunto duly authorized, all as of the date first written
above.

 

	
  TALECRIS BIOTHERAPEUTICS, INC.

  	
   

  	
  BAYER HEALTHCARE LLC

  
	
   

  	
   

  	
   

  
	
  BY:

  	
  /s/ Authorized Signatory

  	
   

  	
  BY:

  	
  /s/ Authorized Signatory

  
	
   

  	
   

  	
   

  	
   

  
	
  TITLE:

  	
  Authorized Signatory

  	
   

  	
  TITLE:

  	
  Authorized Signatory

  
	
   

  	
   

  	
   

  	
   

  
	
  DATE:

  	
  6/27/06

  	
   

  	
  DATE:

  	
  6/19/06

  
										

 

15

 

Amended and Restated Master Services Agreement

Exhibits A-E: [***]

 

[*** 7
pages redacted]

 

***
CONFIDENTIAL TREATMENT REQUESTED

 

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]